2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T747,Docetaxel improves survival in metastatic hormone-sensitive prostate cancer (mHSPC) and high-risk localized disease, but benefits vary substantially among patients. Without predictive biomarkers, clinicians cannot identify patients who will benefit, exposing many to unnecessary toxicity. We developed and validated an artificial intelligence-based pathology image classifier (APIC) to predict docetaxel benefit. We analyzed digitized H&E-stained biopsy specimens from two phase 3 trials: CHAARTED (286/790 patients with mHSPC) and NRG/RTOG 0521 (350/563 patients with high-risk localized disease). APIC used features capturing tumor-immune spatial interactions and nuclear heterogeneity. We evaluated the predictive value of APIC for docetaxel benefit on overall survival and castration-resistance using Cox proportional hazards with interaction terms. In CHAARTED, APIC-positive patients (56.7%) showed significant overall survival improvement with docetaxel (hazard ratio [HR] 0.52, 95% confidence interval [CI] 0.31-0.85; P = 0.008) and delayed castration-resistance (HR 0.48, 95% CI 0.33-0.71; P < 0.001), while APIC-negative patients (43.3%) showed no benefit (HR 1.31, 95% CI 0.71-2.44; P = 0.39). Treatment-APIC interactions were significant (P = 0.022 and P = 0.031). In NRG/RTOG 0521, APIC-positive patients (44.7%) demonstrated survival benefit (HR 0.49, 95% CI 0.26-0.92; P = 0.023), while APIC-negative patients (55.3%) showed no benefit. Treatment-APIC interaction was significant (P = 0.024). Predictive value remained significant after adjusting for clinical variables. Limitations include retrospective analysis and need for prospective validation. APIC predicts docetaxel benefit in both metastatic and localized prostate cancer, independent of clinical factors. Validation in triplet therapy with androgen receptor pathway inhibitors is needed.31:T9ef,Abstract Purpose: Docetaxel improves survival in metastatic hormone-sensitive prostate cancer (mHSPC) and high-risk localized disease, but benefits vary substantially among patients. Without predictive biomarkers, clinicians cannot identify patients who will benefit, exposing many to unnecessary toxicity. We developed and validated an artificial intelligence–based pathology image classifier (APIC) to predict docetaxel benefit. Experimental Design: We analyzed digitized hematoxylin and eosin–stained biopsy specimens from two phase 3 trials: CHAARTED (286/790 patients with mHSPC) and NRG/RTOG 0521 (350/563 patients with high-risk localized disease). APIC used features capturing tumor-immune spatial interactions and nuclear heterogeneity. We evaluated the predictive value of APIC for docetaxel benefit on overall survival (OS) and castration resistance using Cox proportional hazards with interaction terms. Results: In CHAARTED, APIC-positive patients (56.7%) showed significant OS improvement with docetaxel [HR, 0.52; 95% confidence interval (CI), 0.31–0.85; P = 0.008] and delayed castration resistance (HR, 0.48; 95% CI, 0.33–0.71; P < 0.001), whereas APIC-negative patients (43.3%) showed no benefit (HR, 1.31; 95% CI, 0.71–2.44; P = 0.39). Treatment–APIC interactions were significant (P = 0.022 and P = 0.031). In NRG/RTOG 0521, APIC-positive patients (44.7%) demonstrated survival benefit (HR, 0.49; 95% CI, 0.26–0.92; P = 0.023), whereas APIC-negative patients (55.3%) showed no benefit. Treatment–APIC interaction was significant (P = 0.024). Predictive value remained significant after adjusting for clinical variables. Limitations include retrospective analysis and need for prospective validation. Conclusions: APIC predicts docetaxel benefit in both metastatic and localized prostate cancers, independent of clinical factors. Validation in triplet therapy with androgen receptor pathway inhibitors is needed. 32:T63a,Historically, systemic therapy for hormone-sensitive prostate cancer (HSPC) was predicated on androgen-deprivation therapy (ADT) alone. However, in the past decade, substantial improvements have been made by intensifying treatment based on a better understanding of the broad underlying biology of these cancers. The addition of androgen receptor pathway inhibitors (ARPIs), docetaxel and/or radiotherapy to ADT is of proven benefit in certain patient subgroups, whereas AKT inhibitors, radioligand therapies and poly ADP-ribose polymerase (PARP) inhibitors are being evaluated in patients with metastatic HSPC. The clinical states of HSPC are determined by a history of localized prostate cancer versus presentation with de novo metastatic disease, as well as the extent of disease on conventional computed tomography imaging and whole-body bone scintigraphy. However, modern nuclear imaging modalities such as prostate-specific membrane antigen PET can visualize metastases below the limit of detection of computed tomography and whole-body bone scintigraphy; this earlier and more precise detection of metastases has identified new subgroups of patients for which certain treatment approaches, such as adding docetaxel to ADT plus an ARPI, might or might not apply. In this Review, we discuss the personalized management of both non-metastatic and metastatic HSPC, including how to select patients for docetaxel, choice of ARPI and use of radiotherapy to primary and metastatic disease sites. We also discuss emerging novel therapies and important principles of toxicity mitigation for HSPC.33:T628,L.M.B. is a member of the ANZUP Scientific Advisory Committee (unpaid). L.E. reports research grant support (to institution) from Clarity Pharma and Novartis and consulting fees for lectures or advisory boards from Advancell, Astellas, AstraZeneca, Clarity Pharma, Janssen, Novartis and Telix in the past 5 years. C.J.S. declares roles as principal investigator of the CHAARTED trial, study co-chair of the ENZAMET trial and is a member of the ANZUP Scientific Advisory Committee (unpaid); research funding (to institution) from Astellas, Bayer, Janssen, Pfizer and Sanofi; compensated advisory roles for Astellas, Bayer, Genentech/Roche, Hengrui, Janssen, Lilly, Novartis, Pfizer, PointBiopharma and Sanofi; and stock ownership in Leuchemix. C.J.S also holds patents for parthenolide as an anticancer agent, co-authored with H. Nakshatri (WO0145699A1, owned by Indiana University); for use of the drug combination of abiraterone and cabozantinib to treat prostate cancer, co-authors with P. Kantoff (WO 2014/165770 A1 owned by Exelixis); for compositions and methods for screening and diagnosis of prostate cancer with KDM5D biomarker, co-authored with P. Kantoff, G.-S. Mary Lee and K. Komura (WO2017/117486 A1, owned by Dana-Farber Cancer Institute); for compositions and methods for screening and identifying clinically aggressive prostate cancer with SNPs and ZFP36, co-authored with C. Huttenhower, T. Gerke, L. Mucci, G.-S. Mary Lee and D. Bornigen (WO2017127696A, owned by Harvard University and Dana-Farber Cancer Institute). M.A.C. declares no competing interests.34:T465,High-dose radiotherapy is the standard treatment for cutaneous angiosarcoma (CAS); however, adverse events and organ toxicity remain major challenges. Intensity-modulated radiation therapy using tomotherapy allows the precise targeting of complex lesions. We retrospectively reviewed 12 patients with CAS who were treated with tomotherapy and paclitaxel between January 2017 and April 2024. Clinical outcomes, including progression-free survival, overall survival, and adverse events, were analyzed and compared with those of the historical controls. The median progression-free survival was 10.5 months (95% confidence interval: 7.7-not reached). The 2-year overall survival and progression-free survival rates were 70.0% and 41.7%, respectively. Grade ≥ 3 adverse events occurred in a limited number of patients, including radiation-induced dermatitis (n = 1), neutropenia (n = 2), peripheral neuropathy (n = 1), and corneal toxicity (n = 1). Nevertheless, the treatment regimen was generally well tolerated and achieved favorable survival outcomes, representing a safe and effective treatment option.35:T513,ABSTRACTHigh‐dose radiotherapy is the standard treatment for cutaneous angiosarcoma (CAS); however, adverse events and organ toxicity remain major challenges. Intensity‐modulated radiation therapy using tomotherapy allows the precise targeting of complex lesions. We retrospectively reviewed 12 patients with CAS who were treated with tomotherapy and paclitaxel between January 2017 and April 2024. Clinical outcomes, including progression‐free survival, overall survival, and adverse events, were analyzed and compared with those of the historical controls. The median progression‐free survival was 10.5 months (95% confidence interval: 7.7–not reached). The 2‐year overall survival and progression‐free survival rates were 70.0% and 41.7%, respectively. Grade ≥ 3 adverse events occurred in a limited number of patients, including radiation‐induced dermatitis (n = 1), neutropenia (n = 2), peripheral neuropathy (n = 1), and corneal toxicity (n = 1). Nevertheless, the treatment regimen was generally well tolerated and achieved favorable survival outcomes, representing a safe and effective treatment option.36:T439,ABSTRACTA 64‐year‐old woman with progressive thickening of the skin on her left upper limb was referred to our clinic. She had previously undergone partial mastectomy and axillary lymph node dissection for left‐sided breast cancer, followed by postoperative radiation therapy and chemotherapy with docetaxel. She exhibited edema and sclerosis of the left arm and contracture limited to the fingers of the left hand, while her right arm and lower extremities remained unaffected. There were no signs of Raynaud's phenomenon or periungual capillary abnormalities suggestive of systemic sclerosis. Skin biopsy from the left forearm showed dermal thickening with swollen collagen fibers throughout the dermis. A diagnosis of unilateral docetaxel‐induced scleroderma was established. Taxane‐induced scleroderma typically manifests symmetrically in the lower limbs with prominent edema. This report describes a rare case of unilateral upper limb involvement and discusses its characteristics with a review of previously reported cases.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Taxane Chemotherapy: modality Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Taxane Chemotherapy (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/Taxane%20Chemotherapy\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Taxane Chemotherapy\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/Taxane%20Chemotherapy\"}]}}"}}]],["$","$L2f",null,{"title":"Taxane Chemotherapy: Research & Clinical Takeaways","description":"Review evidence by treatment modality: Taxane Chemotherapy — concise summaries and practical next steps.","papers":[{"doi":"10.1038/s41391-026-01124-5","pmid":"42209844","title":"EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression","journal_title":"Prostate Cancer and Prostatic Diseases","journal_issn":"1365-7852","published_at":"2026-05-29T00:00:00.000Z","url":"https://doi.org/10.1038/s41391-026-01124-5","source_score":1,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-08T13:46:34.969Z","updated_at":"2026-06-08T13:46:34.969Z","tags":[{"paper_doi":"10.1038/s41391-026-01124-5","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1038/s41391-026-01124-5","tag_type":"category","value":"Urology & Nephrology","value_numeric":null},{"paper_doi":"10.1038/s41391-026-01124-5","tag_type":"condition","value":"Metastatic Castration-Resistant Prostate Cancer","value_numeric":null},{"paper_doi":"10.1038/s41391-026-01124-5","tag_type":"condition","value":"Metastatic Hormone-Sensitive Prostate Cancer","value_numeric":null},{"paper_doi":"10.1038/s41391-026-01124-5","tag_type":"generic","value":"abiraterone","value_numeric":null},{"paper_doi":"10.1038/s41391-026-01124-5","tag_type":"generic","value":"apalutamide","value_numeric":null},{"paper_doi":"10.1038/s41391-026-01124-5","tag_type":"generic","value":"darolutamide","value_numeric":null},{"paper_doi":"10.1038/s41391-026-01124-5","tag_type":"generic","value":"docetaxel","value_numeric":null},{"paper_doi":"10.1038/s41391-026-01124-5","tag_type":"generic","value":"enzalutamide","value_numeric":null},{"paper_doi":"10.1038/s41391-026-01124-5","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1038/s41391-026-01124-5","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1038/s41391-026-01124-5","tag_type":"modality","value":"Androgen Deprivation Therapy","value_numeric":null},{"paper_doi":"10.1038/s41391-026-01124-5","tag_type":"modality","value":"Androgen Receptor Pathway Inhibitor","value_numeric":null},{"paper_doi":"10.1038/s41391-026-01124-5","tag_type":"modality","value":"Taxane Chemotherapy","value_numeric":null},{"paper_doi":"10.1038/s41391-026-01124-5","tag_type":"sample_size","value":"n=401","value_numeric":401},{"paper_doi":"10.1038/s41391-026-01124-5","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.1038/s41391-026-01124-5","tag_type":"study_design","value":"Retrospective Multicenter Registry Study","value_numeric":null},{"paper_doi":"10.1038/s41391-026-01124-5","tag_type":"warning","value":"Specific ARPIs used are not broken down in the available abstract/results text; brand and generic tags reflect agents mentioned in the reference list and background context rather than confirmed per-patient data.","value_numeric":null},{"paper_doi":"10.1038/s41391-026-01124-5","tag_type":"warning","value":"The level of evidence is rated 4 given the retrospective, non-randomized, registry design.","value_numeric":null},{"paper_doi":"10.1038/s41391-026-01124-5","tag_type":"warning","value":"The study spans 2005–2023, meaning a substantial proportion of patients were treated before combination therapy (ARPI+ADT) became standard, which may confound comparisons between treatment groups.","value_numeric":null},{"paper_doi":"10.1038/s41391-026-01124-5","tag_type":"warning","value":"The total sample size of 401 is inferred by summing the three reported subgroups (201 + 124 + 76); the abstract does not explicitly state the total N.","value_numeric":null}],"summaries":{"practice_takeaway":"Patients with early progression on mHSPC therapy face very poor survival (median OS under 27 months) regardless of the subsequent mCRPC treatment used — no clear best next step has emerged. Clinicians should consider enrolling these patients in clinical trials, as optimal first-line mCRPC therapy remains an unmet need.","what_studied":"This multicentric retrospective registry (EMETPRO) evaluated 401 patients with metastatic hormone-sensitive prostate cancer (mHSPC) who had early progression (EP): ≤6 months on ADT+docetaxel or ADT+ARPI, or ≤9 months on ADT monotherapy, treated between 2005 and 2023 across international centers.","key_result":"Outcomes were poor across all groups. ADT monotherapy patients had median PFS 6.8 months and median OS 26.4 months. ADT+docetaxel patients had median PFS 4.9 months and OS 18.6 months. ADT+ARPI patients had median PFS 5.6 months and OS 19.5 months. Neither first-line mCRPC treatment choice nor genetic profile was associated with improved survival.","limitations":"Retrospective design with data spanning 2005–2023 introduces heterogeneity in treatment eras and standards. Genetic profiling was not available for all patients, limiting biomarker analysis. No randomization; treatment allocation was at physician discretion."}},{"doi":"10.1097/ju.0000000000005131","pmid":"42171515","title":"First-Line Systemic Treatments of Metastatic Hormone-Sensitive Prostate Cancer: Updated Systematic Review and Network Meta-Analysis","journal_title":"Journal of Urology","journal_issn":"0022-5347","published_at":"2026-05-22T00:00:00.000Z","url":"https://doi.org/10.1097/ju.0000000000005131","source_score":8,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-14T13:24:59.421Z","updated_at":"2026-08-14T13:24:59.421Z","tags":[{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"brand","value":"Erleada","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"brand","value":"Nubeqa","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"brand","value":"Pluvicto","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"brand","value":"Xtandi","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"brand","value":"Zytiga","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"category","value":"Urology & Nephrology","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"condition","value":"Metastatic Hormone-Sensitive Prostate Cancer","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"generic","value":"abiraterone","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"generic","value":"apalutamide","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"generic","value":"capivasertib","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"generic","value":"darolutamide","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"generic","value":"docetaxel","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"generic","value":"enzalutamide","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"generic","value":"lutetium-177 PSMA-617","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"generic","value":"niraparib","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"modality","value":"AKT Inhibitor","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"modality","value":"Androgen Deprivation Therapy","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"modality","value":"Androgen Receptor Pathway Inhibitor","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"modality","value":"PARP Inhibitor","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"modality","value":"Radioligand Therapy","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"modality","value":"Taxane Chemotherapy","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"sample_size","value":"n=18689","value_numeric":18689},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"study_design","value":"Network Meta-Analysis","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"warning","value":"Biomarker-driven trials (AMPLITUDE, CAPItello-281, PSMAddition) were excluded from the NMA due to selected populations and evaluated qualitatively only; OS results are immature for all three.","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"warning","value":"PARPi+ARPI+ADT OS data were not available for inclusion in the NMA; OS benefit for this triplet remains unknown.","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"warning","value":"Several included trials had open-label designs, introducing risk of bias in investigator-assessed progression endpoints.","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"warning","value":"The impact_flag 'practice_changing' reflects the high-certainty subgroup finding for docetaxel triplet in high-volume disease and the emerging biomarker-driven data; the all-comer analysis does not confirm a practice change for unselected patients.","value_numeric":null},{"paper_doi":"10.1097/ju.0000000000005131","tag_type":"warning","value":"The NMA grouped all ARPIs (abiraterone, apalutamide, darolutamide, enzalutamide, orteronel, rezvilutamide) as a single class to preserve network connectivity; class-level effects may mask agent-specific differences.","value_numeric":null}],"summaries":{"what_studied":"This updated systematic review and network meta-analysis (NMA) compared the efficacy and safety of first-line systemic combination therapies for metastatic hormone-sensitive prostate cancer (mHSPC) across 23 RCTs (n=18,689), searched through March 2026. Outcomes included progression-free survival (PFS), overall survival (OS), and severe adverse events (AEs), with a separate systematic review of biomarker-driven trials (AMPLITUDE, CAPItello-281, PSMAddition).","key_result":"No triplet regimen showed a statistically significant OS benefit over ARPI+ADT in all-comers. However, **docetaxel+ARPI+ADT** significantly improved OS in high-volume disease (HR 0.76, 95% CI 0.61–0.95; high certainty). For PFS, docetaxel+ARPI+ADT (HR 0.66, 95% CI 0.43–1.01; moderate certainty) and PARPi+ARPI+ADT (HR 0.55, 95% CI 0.23–1.34; low certainty) showed clinically relevant but non-significant trends vs. ARPI+ADT. In biomarker-selected populations: niraparib+abiraterone improved rPFS in HRR-mutated mHSPC (HR 0.63); capivasertib+abiraterone improved rPFS in PTEN-deficient mHSPC (HR 0.81); Lu-177-PSMA+ARPI+ADT improved rPFS in PSMA-positive mHSPC (HR 0.72); OS data remain immature for all three.","limitations":"- Direct head-to-head comparisons between key triplet regimens were unavailable, requiring reliance on indirect NMA contrasts with interstudy heterogeneity.\n- Combining radiographic and clinical PFS endpoints introduced heterogeneity; earlier trials used conventional imaging vs. more sensitive modalities in recent trials, risking stage migration bias.\n- PARPi-, PSMA-, and AKT-based evidence comes from single trials with immature OS data and small phase II samples, yielding low or very low certainty.","practice_takeaway":"For patients with **high-volume mHSPC**, docetaxel+ARPI+ADT offers a proven OS benefit (HR 0.76; high certainty) and should be preferred. For patients with specific biomarkers (HRR mutation, PTEN loss, or PSMA-positive disease), targeted intensification with PARPi, AKT inhibitor, or radioligand therapy respectively shows rPFS benefit—but OS data are still maturing, so treatment decisions must weigh distinct toxicity profiles against uncertain long-term gains."}},{"doi":"10.1158/1078-0432.ccr-25-3327","pmid":"41324555","title":"A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer","journal_title":"Clinical Cancer Research","journal_issn":"1078-0432","published_at":"2025-12-01T00:00:00.000Z","url":"https://doi.org/10.1158/1078-0432.ccr-25-3327","source_score":44,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-08","doi":"10.1158/1078-0432.ccr-25-3327","days":"7","issn":"1078-0432","rank":"10","field":"Clinical Medicine","score":"44","category":"Oncology","categories":["Oncology"],"_categories":["Oncology"]},"pubmed":{"doi":"10.1158/1078-0432.CCR-25-3327","title":"A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","methods":"","results":"In CHAARTED, APIC-positive patients (56.7%) showed significant overall survival improvement with docetaxel (hazard ratio [HR] 0.52, 95% confidence interval [CI] 0.31-0.85; P = 0.008) and delayed castration-resistance (HR 0.48, 95% CI 0.33-0.71; P < 0.001), while APIC-negative patients (43.3%) showed no benefit (HR 1.31, 95% CI 0.71-2.44; P = 0.39). Treatment-APIC interactions were significant (P = 0.022 and P = 0.031). In NRG/RTOG 0521, APIC-positive patients (44.7%) demonstrated survival benefit (HR 0.49, 95% CI 0.26-0.92; P = 0.023), while APIC-negative patients (55.3%) showed no benefit. Treatment-APIC interaction was significant (P = 0.024). Predictive value remained significant after adjusting for clinical variables. Limitations include retrospective analysis and need for prospective validation.","abstract":"$30","keywords":[],"pubmed_id":"41324555","conclusions":"","publication_date":"2025-12-01T00:00:00"},"crossref":{"DOI":"10.1158/1078-0432.ccr-25-3327","URL":"https://doi.org/10.1158/1078-0432.ccr-25-3327","ISSN":["1078-0432","1557-3265"],"link":[{"URL":"https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-25-3327/3708349/ccr-25-3327.pdf","content-type":"application/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-25-3327/3718903/ccr-25-3327.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-25-3327/3718903/ccr-25-3327.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"OF1-OF9","type":"journal-article","issue":null,"score":1,"title":["A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer"],"author":[{"given":"Sebastian","family":"Medina","sequence":"first","affiliation":[{"name":"1The Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, Atlanta, Georgia."}]},{"given":"Naoto","family":"Tokuyama","sequence":"additional","affiliation":[{"name":"1The Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, Atlanta, Georgia."}]},{"given":"Kamal","family":"Hammouda","sequence":"additional","affiliation":[{"name":"1The Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, Atlanta, Georgia."},{"name":"2Atlanta Veterans Affairs Medical Center, Atlanta, Georgia."},{"name":"3Mathematics Department, Faculty of Science, Mansoura University, Mansoura, Egypt."}]},{"given":"Tilak","family":"Pathak","sequence":"additional","affiliation":[{"name":"1The Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, Atlanta, Georgia."}]},{"given":"Tuomas","family":"Mirtti","sequence":"additional","affiliation":[{"name":"4Helsinki University Hospital, Helsinki, Finland."}]},{"given":"Pingfu","family":"Fu","sequence":"additional","affiliation":[{"name":"5Case Western Reserve University, Cleveland, Ohio."}]},{"given":"Shilpa","family":"Gupta","sequence":"additional","affiliation":[{"name":"6Cleveland Clinic, Cleveland, Ohio."}]},{"given":"Priti","family":"Lal","sequence":"additional","affiliation":[{"name":"7University of Pennsylvania, Philadelphia, Pennsylvania."}]},{"given":"Howard M.","family":"Sandler","sequence":"additional","affiliation":[{"name":"8Cedars-Sinai Medical Center, Los Angeles, California."}]},{"given":"Rohann","family":"Correa","sequence":"additional","affiliation":[{"name":"9London Health Science Centre, London, Canada."}]},{"given":"Susan","family":"Chafe","sequence":"additional","affiliation":[{"name":"10Cross Cancer Institute, Edmonton, Canada."}]},{"given":"Amit","family":"Shah","sequence":"additional","affiliation":[{"name":"11WellSpan Health, York, Pennsylvania."}]},{"given":"Jason A.","family":"Efstathiou","sequence":"additional","affiliation":[{"name":"12Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts."}]},{"given":"Karen","family":"Hoffman","sequence":"additional","affiliation":[{"name":"13The University of Texas MD Anderson Cancer Center, Houston, Texas."}]},{"given":"Michael","family":"Straza","sequence":"additional","affiliation":[{"name":"14Medical College of Wisconsin, Milwaukee, Wisconsin."}]},{"given":"Mark A.","family":"Hallman","sequence":"additional","affiliation":[{"name":"15Fox Chase Cancer Center, Philadelphia, Pennsylvania."}]},{"given":"Richard","family":"Jordan","sequence":"additional","affiliation":[{"name":"16NRG Oncology Biospecimen Bank, San Francisco, California."}]},{"given":"Stephanie L.","family":"Pugh","sequence":"additional","affiliation":[{"name":"17NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania."}]},{"given":"Christopher J.","family":"Sweeney","sequence":"additional","affiliation":[{"name":"18South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia."}]},{"given":"Anant","family":"Madabhushi","sequence":"additional","affiliation":[{"name":"1The Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, Atlanta, Georgia."},{"name":"2Atlanta Veterans Affairs Medical Center, Atlanta, Georgia."}]}],"funder":[{"id":[{"id":"10.13039/100000054","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000054","name":"National Cancer Institute","award":["R01CA268287A1"],"award-info":[{"award-number":["R01CA268287A1"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000054","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000054","name":"National Cancer Institute","award":["R01CA26828703"],"award-info":[{"award-number":["R01CA26828703"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000054","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000054","name":"National Cancer Institute","award":["U01CA269181"],"award-info":[{"award-number":["U01CA269181"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000054","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000054","name":"National Cancer Institute","award":["R01CA26820701A1"],"award-info":[{"award-number":["R01CA26820701A1"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000054","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000054","name":"National Cancer Institute","award":["R01CA249992-01A1"],"award-info":[{"award-number":["R01CA249992-01A1"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000054","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000054","name":"National Cancer Institute","award":["R01CA202752-01A1"],"award-info":[{"award-number":["R01CA202752-01A1"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000054","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000054","name":"National Cancer Institute","award":["R01CA208236-01A1"],"award-info":[{"award-number":["R01CA208236-01A1"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000054","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000054","name":"National Cancer Institute","award":["R01CA216579-01A1"],"award-info":[{"award-number":["R01CA216579-01A1"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000054","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000054","name":"National Cancer Institute","award":["R01CA220581-01A1"],"award-info":[{"award-number":["R01CA220581-01A1"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000054","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000054","name":"National Cancer Institute","award":["R01CA257612-01A1"],"award-info":[{"award-number":["R01CA257612-01A1"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000054","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000054","name":"National Cancer Institute","award":["1U01CA239055-01"],"award-info":[{"award-number":["1U01CA239055-01"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000054","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000054","name":"National Cancer Institute","award":["1U01CA248226-01"],"award-info":[{"award-number":["1U01CA248226-01"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000054","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000054","name":"National Cancer Institute","award":["1U54CA254566-01"],"award-info":[{"award-number":["1U54CA254566-01"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000054","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000054","name":"National Cancer Institute","award":["U10CA180820"],"award-info":[{"award-number":["U10CA180820"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000054","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000054","name":"National Cancer Institute","award":["UG1CA233247"],"award-info":[{"award-number":["UG1CA233247"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000054","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000054","name":"National Cancer Institute","award":["UG1CA233234"],"award-info":[{"award-number":["UG1CA233234"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000054","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000054","name":"National Cancer Institute","award":["UG1CA189867"],"award-info":[{"award-number":["UG1CA189867"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000054","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000054","name":"National Cancer Institute","award":["U10CA180868"],"award-info":[{"award-number":["U10CA180868"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000054","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000054","name":"National Cancer Institute","award":["U10CA180822"],"award-info":[{"award-number":["U10CA180822"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000054","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000054","name":"National Cancer Institute","award":["U24CA196067"],"award-info":[{"award-number":["U24CA196067"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000002","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000002","name":"National Institutes of Health","award":["T32DK108735"],"award-info":[{"award-number":["T32DK108735"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000050","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000050","name":"National Heart, Lung, and Blood Institute","award":["1R01HL15127701A1"],"award-info":[{"award-number":["1R01HL15127701A1"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000050","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000050","name":"National Heart, Lung, and Blood Institute","award":["R01HL15807101A1"],"award-info":[{"award-number":["R01HL15807101A1"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000070","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","award":["1R43EB028736-01"],"award-info":[{"award-number":["1R43EB028736-01"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000738","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000738","name":"U.S. Department of Veterans Affairs","award":["IBX004121A"],"award-info":[{"award-number":["IBX004121A"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000005","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000005","name":"U.S. Department of Defense","award":["W81XWH-19-1-0668"],"award-info":[{"award-number":["W81XWH-19-1-0668"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000005","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000005","name":"U.S. Department of Defense","award":["W81XWH-20-1-0851"],"award-info":[{"award-number":["W81XWH-20-1-0851"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000005","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000005","name":"U.S. Department of Defense","award":["W81XWH-18-1-0440"],"award-info":[{"award-number":["W81XWH-18-1-0440"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000005","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000005","name":"U.S. Department of Defense","award":["W81XWH-20-1-0595"],"award-info":[{"award-number":["W81XWH-20-1-0595"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000005","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000005","name":"U.S. Department of Defense","award":["W81XWH-18-1-0404"],"award-info":[{"award-number":["W81XWH-18-1-0404"]}],"doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000005","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000005","name":"U.S. Department of Defense","award":["W81XWH-21"],"award-info":[{"award-number":["W81XWH-21"]}],"doi-asserted-by":"publisher"},{"name":"Kidney Precision Medicine Project","award":["Glue Grant"],"award-info":[{"award-number":["Glue Grant"]}]}],"issued":{"date-parts":[[2025,12,29]]},"member":"1086","prefix":"10.1158","source":"Crossref","volume":null,"created":{"date-time":"2025-12-01T15:40:02Z","timestamp":1764603602000,"date-parts":[[2025,12,1]]},"indexed":{"date-time":"2025-12-29T15:02:39Z","timestamp":1767020559830,"date-parts":[[2025,12,29]]},"license":[{"URL":"https://creativecommons.org/licenses/by-nc-nd/4.0/","start":{"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000,"date-parts":[[2025,12,29]]},"delay-in-days":0,"content-version":"unspecified"}],"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-25-3327/771216/A-Computational-Pathology-Model-to-Predict"}},"subtitle":[],"deposited":{"date-time":"2025-12-29T14:58:09Z","timestamp":1767020289000,"date-parts":[[2025,12,29]]},"issn-type":[{"type":"print","value":"1078-0432"},{"type":"electronic","value":"1557-3265"}],"published":{"date-parts":[[2025,12,29]]},"publisher":"American Association for Cancer Research (AACR)","reference":null,"short-title":[],"update-policy":"https://doi.org/10.1158/crossmark_policy","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"original-title":[],"container-title":["Clinical Cancer Research"],"reference-count":0,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,12,29]]},"references-count":0,"short-container-title":[],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1158/1078-0432.ccr-25-3327","is_oa":true,"title":"A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer","updated":"2025-12-04T15:52:58+00:00","published_date":"2025-12-01","best_oa_location":{"url":"https://doi.org/10.1158/1078-0432.ccr-25-3327","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.1158/1078-0432.ccr-25-3327"}}},"created_at":"2026-01-15T20:51:27.064Z","updated_at":"2026-01-15T20:51:27.064Z","tags":[{"paper_doi":"10.1158/1078-0432.ccr-25-3327","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-3327","tag_type":"condition","value":"High-Risk Localized Prostate Cancer","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-3327","tag_type":"condition","value":"Metastatic Hormone-Sensitive Prostate Cancer","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-3327","tag_type":"generic","value":"docetaxel","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-3327","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-3327","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-3327","tag_type":"modality","value":"Taxane Chemotherapy","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-3327","tag_type":"sample_size","value":"n=636","value_numeric":636},{"paper_doi":"10.1158/1078-0432.ccr-25-3327","tag_type":"study_design","value":"Retrospective Cohort","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-3327","tag_type":"warning","value":"Absolute survival rates and follow-up durations were not provided in the abstract.","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-3327","tag_type":"warning","value":"Design classification is approximate: this is a retrospective biomarker analysis of subsets from two phase 3 trials, not a randomized test of the classifier.","value_numeric":null},{"paper_doi":"10.1158/1078-0432.ccr-25-3327","tag_type":"warning","value":"Only subsets with available digitized biopsies were included, which may limit generalizability.","value_numeric":null}],"summaries":{"what_studied":"Retrospective analyses of two phase 3 trials (CHAARTED: 286/790 with mHSPC; NRG/RTOG 0521: 350/563 with high‑risk localized disease) evaluated an AI pathology image classifier (APIC) on H&E biopsies to predict which patients gain survival benefit from docetaxel using Cox models with treatment-by-APIC interaction.","key_result":"In CHAARTED, APIC‑positive patients (56.7%) had improved overall survival with docetaxel (HR 0.52, 95% CI 0.31–0.85; P=0.008) and delayed castration‑resistance (HR 0.48, 95% CI 0.33–0.71; P<0.001), while APIC‑negative patients (43.3%) did not (OS HR 1.31, 95% CI 0.71–2.44; P=0.39); treatment‑APIC interactions were significant (P=0.022 and P=0.031). In NRG/RTOG 0521, APIC‑positive patients (44.7%) showed an OS benefit (HR 0.49, 95% CI 0.26–0.92; P=0.023), APIC‑negative patients did not, and the interaction was significant (P=0.024); effects persisted after adjustment for clinical variables.","limitations":"Retrospective analysis; findings require prospective validation. Only subsets of trial participants with available digitized biopsies were analyzed (CHAARTED 286/790; NRG/RTOG 0521 350/563).","practice_takeaway":"APIC appears to identify which patients with mHSPC or high‑risk localized prostate cancer benefit from docetaxel, while others may not. Until prospectively validated, use is exploratory and should not replace current selection criteria."}},{"doi":"10.1038/s41571-025-01100-3","pmid":"41310272","title":"Personalized intensification of treatment for hormone-sensitive prostate cancer","journal_title":"Nature Reviews Clinical Oncology","journal_issn":"1759-4774","published_at":"2025-11-28T00:00:00.000Z","url":"https://doi.org/10.1038/s41571-025-01100-3","source_score":86,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-12-02","doi":"10.1038/s41571-025-01100-3","days":"7","issn":"1759-4774","rank":"3","field":"Clinical Medicine","score":"86","category":"Oncology","categories":["Oncology"],"_categories":["Oncology"]},"pubmed":{"doi":"10.1038/s41571-025-01100-3","title":"Personalized intensification of treatment for hormone-sensitive prostate cancer.","journal":"Nature reviews. Clinical oncology","methods":"","results":"","abstract":"$32","keywords":[],"pubmed_id":"41310272","conclusions":"","publication_date":"2025-11-28T00:00:00"},"crossref":{"DOI":"10.1038/s41571-025-01100-3","URL":"https://doi.org/10.1038/s41571-025-01100-3","ISSN":["1759-4774","1759-4782"],"link":[{"URL":"https://www.nature.com/articles/s41571-025-01100-3.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https://www.nature.com/articles/s41571-025-01100-3","content-type":"text/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https://www.nature.com/articles/s41571-025-01100-3.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Personalized intensification of treatment for hormone-sensitive prostate cancer"],"author":[{"given":"Michael A.","family":"Cilento","sequence":"first","affiliation":[]},{"given":"Lisa M.","family":"Butler","sequence":"additional","affiliation":[]},{"given":"Louise","family":"Emmett","sequence":"additional","affiliation":[]},{"given":"Christopher J.","family":"Sweeney","sequence":"additional","affiliation":[]}],"issued":{"date-parts":[[2025,11,27]]},"member":"297","prefix":"10.1038","source":"Crossref","volume":null,"created":{"date-time":"2025-11-27T11:39:32Z","timestamp":1764243572000,"date-parts":[[2025,11,27]]},"indexed":{"date-time":"2025-11-27T13:05:20Z","timestamp":1764248720499,"date-parts":[[2025,11,27]]},"license":[{"URL":"https://www.springernature.com/gp/researchers/text-and-data-mining","start":{"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000,"date-parts":[[2025,11,27]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://www.springernature.com/gp/researchers/text-and-data-mining","start":{"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000,"date-parts":[[2025,11,27]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://www.nature.com/articles/s41571-025-01100-3"}},"subtitle":[],"assertion":[{"name":"accepted","group":{"name":"ArticleHistory","label":"Article History"},"label":"Accepted","order":1,"value":"29 October 2025"},{"name":"first_online","group":{"name":"ArticleHistory","label":"Article History"},"label":"First Online","order":2,"value":"27 November 2025"},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"},"order":1,"value":"$33"}],"deposited":{"date-time":"2025-11-27T13:02:54Z","timestamp":1764248574000,"date-parts":[[2025,11,27]]},"issn-type":[{"type":"print","value":"1759-4774"},{"type":"electronic","value":"1759-4782"}],"published":{"date-parts":[[2025,11,27]]},"publisher":"Springer Science and Business Media LLC","reference":[{"DOI":"10.1002/ijc.35278","key":"1100_CR1","year":"2024","issue":null,"author":"AM Filho","volume":"156","first-page":"1336","unstructured":"Filho, A. M. et al. The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide. Int. J. Cancer 156, 1336–1346 (2024).","article-title":null,"journal-title":"Int. J. Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(24)00651-2","key":"1100_CR2","year":"2024","issue":null,"author":"ND James","volume":"403","first-page":"1683","unstructured":"James, N. D. et al. The lancet commission on prostate cancer: planning for the surge in cases. Lancet 403, 1683–1722 (2024).","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1093/jnci/djaa068","key":"1100_CR3","year":"2021","issue":null,"author":"A Jemal","volume":"113","first-page":"64","unstructured":"Jemal, A., Culp, M. B., Ma, J., Islami, F. & Fedewa, S. A. Prostate cancer incidence 5 years after US preventive services task force recommendations against screening. J. Natl Cancer Inst. 113, 64–71 (2021).","article-title":null,"journal-title":"J. Natl Cancer Inst.","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2214122","key":"1100_CR4","year":"2023","issue":null,"author":"FC Hamdy","volume":"388","first-page":"1547","unstructured":"Hamdy, F. C. et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N. Engl. J. Med. 388, 1547–1558 (2023).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(21)02437-5","key":"1100_CR5","year":"2022","issue":null,"author":"G Attard","volume":"399","first-page":"447","unstructured":"Attard, G. et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet 399, 447–460 (2022).","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1002/cncr.31384","key":"1100_CR6","year":"2018","issue":null,"author":"JT Helgstrand","volume":"124","first-page":"2931","unstructured":"Helgstrand, J. T. et al. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-a population-based analysis of 2 national cohorts. Cancer 124, 2931–2938 (2018).","article-title":null,"journal-title":"Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eururo.2024.03.027","key":"1100_CR7","year":"2024","issue":null,"author":"P Cornford","volume":"86","first-page":"148","unstructured":"Cornford, P. et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur. Urol. 86, 148–163 (2024).","article-title":null,"journal-title":"Eur. Urol.","doi-asserted-by":"publisher"},{"DOI":null,"key":"1100_CR8","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer V.1.2025. National Comprehensive Cancer Network https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (accessed 31 January 2025).","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/j.urology.2007.08.055","key":"1100_CR9","year":"2007","issue":null,"author":"DJ Hernandez","volume":"70","first-page":"931","unstructured":"Hernandez, D. J., Nielsen, M. E., Han, M. & Partin, A. W. Contemporary evaluation of the D’amico risk classification of prostate cancer. Urology 70, 931–935 (2007).","article-title":null,"journal-title":"Urology","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ijrobp.2022.12.035","key":"1100_CR10","year":"2023","issue":null,"author":"PL Nguyen","volume":"116","first-page":"521","unstructured":"Nguyen, P. L. et al. Analysis of a biopsy-based genomic classifier in high-risk prostate cancer: meta-analysis of the nrg oncology/radiation therapy oncology group 9202, 9413, and 9902 phase 3 randomized trials. Int. J. Radiat. Oncol. Biol. Phys. 116, 521–529 (2023).","article-title":null,"journal-title":"Int. J. Radiat. Oncol. Biol. Phys.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eururo.2017.09.013","key":"1100_CR11","year":"2018","issue":null,"author":"SK Van Den Eeden","volume":"73","first-page":"129","unstructured":"Van Den Eeden, S. K. et al. A Biopsy-based 17-gene Genomic prostate score as a predictor of metastases and prostate cancer death in surgically treated men with clinically localized disease. Eur. Urol. 73, 129–138 (2018).","article-title":null,"journal-title":"Eur. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(10)70295-3","key":"1100_CR12","year":"2011","issue":null,"author":"J Cuzick","volume":"12","first-page":"245","unstructured":"Cuzick, J. et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 12, 245–255 (2011).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.euo.2024.01.004","key":"1100_CR13","year":"2024","issue":null,"author":"AE Ross","volume":"7","first-page":"1024","unstructured":"Ross, A. E. et al. External validation of a digital pathology-based multimodal artificial intelligence architecture in the NRG/RTOG 9902 phase 3 trial. Eur. Urol. Oncol. 7, 1024–1033 (2024).","article-title":null,"journal-title":"Eur. Urol. Oncol.","doi-asserted-by":"publisher"},{"DOI":null,"key":"1100_CR14","year":"1941","issue":null,"author":"C Huggins","volume":"1","first-page":"293","unstructured":"Huggins, C. & Hodges, C. V. Studies on prostatic cancer. I. the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1, 293–297 (1941).","article-title":null,"journal-title":"Cancer Res.","doi-asserted-by":null},{"DOI":"10.1056/NEJMoa2303974","key":"1100_CR15","year":"2023","issue":null,"author":"SJ Freedland","volume":"389","first-page":"1453","unstructured":"Freedland, S. J. et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N. Engl. J. Med. 389, 1453–1465 (2023).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1002/cncr.25993","key":"1100_CR16","year":"2011","issue":null,"author":"SE Cotter","volume":"117","first-page":"3925","unstructured":"Cotter, S. E. et al. Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer 117, 3925–3932 (2011).","article-title":null,"journal-title":"Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(20)31553-1","key":"1100_CR17","year":"2020","issue":null,"author":"CC Parker","volume":"396","first-page":"1413","unstructured":"Parker, C. C. et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet 396, 1413–1421 (2020).","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(20)30456-3","key":"1100_CR18","year":"2020","issue":null,"author":"A Kneebone","volume":"21","first-page":"1331","unstructured":"Kneebone, A. et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol. 21, 1331–1340 (2020).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(20)30454-X","key":"1100_CR19","year":"2020","issue":null,"author":"P Sargos","volume":"21","first-page":"1341","unstructured":"Sargos, P. et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol. 21, 1341–1352 (2020).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(19)30486-3","key":"1100_CR20","year":"2019","issue":null,"author":"C Carrie","volume":"20","first-page":"1740","unstructured":"Carrie, C. et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 20, 1740–1749 (2019).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(21)01790-6","key":"1100_CR21","year":"2022","issue":null,"author":"A Pollack","volume":"399","first-page":"1886","unstructured":"Pollack, A. et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet 399, 1886–1901 (2022).","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eururo.2024.07.026","key":"1100_CR22","year":"2024","issue":null,"author":"CC Parker","volume":"86","first-page":"422","unstructured":"Parker, C. C. et al. Randomised trial of no, short-term, or long-term androgen deprivation therapy with postoperative radiotherapy after radical prostatectomy: results from the three-way comparison of RADICALS-HD (NCT00541047). Eur. Urol. 86, 422–430 (2024).","article-title":null,"journal-title":"Eur. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1607529","key":"1100_CR23","year":"2017","issue":null,"author":"WU Shipley","volume":"376","first-page":"417","unstructured":"Shipley, W. U. et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N. Engl. J. Med. 376, 417–428 (2017).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41391-025-00937-0","key":"1100_CR24","year":"2025","issue":null,"author":"P Ravi","volume":null,"first-page":null,"unstructured":"Ravi, P. et al. Evaluation of clinical risk stratification to determine benefit from long-term versus short-term androgen deprivation in high-risk localized prostate cancer. Prostate Cancer Prostatic Dis. https://doi.org/10.1038/s41391-025-00937-0 (2025).","article-title":null,"journal-title":"Prostate Cancer Prostatic Dis.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eururo.2020.11.010","key":"1100_CR25","year":"2021","issue":null,"author":"LF Valle","volume":"80","first-page":"280","unstructured":"Valle, L. F. et al. A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER). Eur. Urol. 80, 280–292 (2021).","article-title":null,"journal-title":"Eur. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eururo.2024.04.010","key":"1100_CR26","year":"2024","issue":null,"author":"D Tilki","volume":"86","first-page":"164","unstructured":"Tilki, D. et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. part II-2024 update: treatment of relapsing and metastatic prostate cancer. Eur. Urol. 86, 164–182 (2024).","article-title":null,"journal-title":"Eur. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1097/JU.0000000000001375","key":"1100_CR27","year":"2021","issue":null,"author":"WT Lowrance","volume":"205","first-page":"14","unstructured":"Lowrance, W. T. et al. Advanced prostate cancer: AUA/ASTRO/SUO guideline PART I. J. Urol. 205, 14–21 (2021).","article-title":null,"journal-title":"J. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.20.03256","key":"1100_CR28","year":"2021","issue":null,"author":"KS Virgo","volume":"39","first-page":"1274","unstructured":"Virgo, K. S. et al. Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update. J. Clin. Oncol. 39, 1274–1305 (2021).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1097/PAS.0000000000000530","key":"1100_CR29","year":"2016","issue":null,"author":"JI Epstein","volume":"40","first-page":"244","unstructured":"Epstein, J. I. et al. The 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am. J. Surg. Pathol. 40, 244–252 (2016).","article-title":null,"journal-title":"Am. J. Surg. Pathol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eururo.2019.03.016","key":"1100_CR30","year":"2019","issue":null,"author":"D Tilki","volume":"75","first-page":"896","unstructured":"Tilki, D., Preisser, F., Graefen, M., Huland, H. & Pompe, R. S. External validation of the european association of urology biochemical recurrence risk groups to predict metastasis and mortality after radical prostatectomy in a european cohort. Eur. Urol. 75, 896–900 (2019).","article-title":null,"journal-title":"Eur. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(16)00107-8","key":"1100_CR31","year":"2016","issue":null,"author":"GM Duchesne","volume":"17","first-page":"727","unstructured":"Duchesne, G. M. et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 17, 727–737 (2016).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(17)30426-6","key":"1100_CR32","year":"2017","issue":null,"author":"GM Duchesne","volume":"18","first-page":"1192","unstructured":"Duchesne, G. M. et al. Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 18, 1192–1201 (2017).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.23.01157","key":"1100_CR33","year":"2024","issue":null,"author":"R Aggarwal","volume":"42","first-page":"1114","unstructured":"Aggarwal, R. et al. PRESTO: a phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19). J. Clin. Oncol. 42, 1114–1123 (2024).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1201546","key":"1100_CR34","year":"2012","issue":null,"author":"JM Crook","volume":"367","first-page":"895","unstructured":"Crook, J. M. et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N. Engl. J. Med. 367, 895–903 (2012).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1056/EVIDoa2300251","key":"1100_CR35","year":"2023","issue":null,"author":"SJ Freedland","volume":"2","first-page":"EVIDoa2300251","unstructured":"Freedland, S. J. et al. Enzalutamide and quality of life in biochemically recurrent prostate cancer. NEJM Evid. 2, EVIDoa2300251 (2023).","article-title":null,"journal-title":"NEJM Evid.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2017.73.9987","key":"1100_CR36","year":"2017","issue":null,"author":"W Xie","volume":"35","first-page":"3097","unstructured":"Xie, W. et al. Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J. Clin. Oncol. 35, 3097–3104 (2017).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2510310","key":"1100_CR37","year":"2025","issue":null,"author":"ND Shore","volume":null,"first-page":null,"unstructured":"Shore, N. D. et al. Improved survival with enzalutamide in biochemically recurrent prostate cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2510310 (2025).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(20)30730-0","key":"1100_CR38","year":"2021","issue":null,"author":"LA Gharzai","volume":"22","first-page":"402","unstructured":"Gharzai, L. A. et al. Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. Lancet Oncol. 22, 402–410 (2021).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO-25-01693","key":"1100_CR39","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Einstein, D. J. et al. National Cancer Institute’s Working Group on biochemically recurrent prostate cancer: clinical trial design considerations. J. Clin. Oncol. https://doi.org/10.1200/JCO-25-01693.","article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/jamanetworkopen.2024.52971","key":"1100_CR40","year":"2025","issue":null,"author":"A Holzgreve","volume":"8","first-page":null,"unstructured":"Holzgreve, A. et al. PSMA-PET/CT findings in patients with high-risk biochemically recurrent prostate cancer with no metastatic disease by conventional imaging. JAMA Netw. Open. 8, e2452971 (2025).","article-title":null,"journal-title":"JAMA Netw. Open.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(20)30314-7","key":"1100_CR41","year":"2020","issue":null,"author":"MS Hofman","volume":"395","first-page":"1208","unstructured":"Hofman, M. S. et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395, 1208–1216 (2020).","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1503747","key":"1100_CR42","year":"2015","issue":null,"author":"CJ Sweeney","volume":"373","first-page":"737","unstructured":"Sweeney, C. J. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373, 737–746 (2015).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(15)01037-5","key":"1100_CR43","year":"2016","issue":null,"author":"ND James","volume":"387","first-page":"1163","unstructured":"James, N. D. et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387, 1163–1177 (2016).","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2119115","key":"1100_CR44","year":"2022","issue":null,"author":"MR Smith","volume":"386","first-page":"1132","unstructured":"Smith, M. R. et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N. Engl. J. Med. 386, 1132–1142 (2022).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(22)00367-1","key":"1100_CR45","year":"2022","issue":null,"author":"K Fizazi","volume":"399","first-page":"1695","unstructured":"Fizazi, K. et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet 399, 1695–1707 (2022).","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1704174","key":"1100_CR46","year":"2017","issue":null,"author":"K Fizazi","volume":"377","first-page":"352","unstructured":"Fizazi, K. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 377, 352–360 (2017).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1002/ijc.34018","key":"1100_CR47","year":"2022","issue":null,"author":"ND James","volume":"151","first-page":"422","unstructured":"James, N. D. et al. Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). Int. J. Cancer 151, 422–434 (2022).","article-title":null,"journal-title":"Int. J. Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1903307","key":"1100_CR48","year":"2019","issue":null,"author":"KN Chi","volume":"381","first-page":"13","unstructured":"Chi, K. N. et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 381, 13–24 (2019).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1903835","key":"1100_CR49","year":"2019","issue":null,"author":"ID Davis","volume":"381","first-page":"121","unstructured":"Davis, I. D. et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N. Engl. J. Med. 381, 121–131 (2019).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO-24-01798","key":"1100_CR50","year":"2024","issue":null,"author":"F Saad","volume":"42","first-page":"4271","unstructured":"Saad, F. et al. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. J. Clin. Oncol. 42, 4271–4281 (2024).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(18)32486-3","key":"1100_CR51","year":"2018","issue":null,"author":"CC Parker","volume":"392","first-page":"2353","unstructured":"Parker, C. C. et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392, 2353–2366 (2018).","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2017.75.3657","key":"1100_CR52","year":"2018","issue":null,"author":"CE Kyriakopoulos","volume":"36","first-page":"1080","unstructured":"Kyriakopoulos, C. E. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J. Clin. Oncol. 36, 1080–1087 (2018).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1093/annonc/mdz396","key":"1100_CR53","year":"2019","issue":null,"author":"NW Clarke","volume":"30","first-page":"1992","unstructured":"Clarke, N. W. et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann. Oncol. 30, 1992–2003 (2019).","article-title":null,"journal-title":"Ann. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(23)00230-9","key":"1100_CR54","year":"2023","issue":null,"author":"CL Vale","volume":"24","first-page":"783","unstructured":"Vale, C. L. et al. Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials. Lancet Oncol. 24, 783–797 (2023).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(12)70560-0","key":"1100_CR55","year":"2013","issue":null,"author":"G Gravis","volume":"14","first-page":"149","unstructured":"Gravis, G. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 14, 149–158 (2013).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1702900","key":"1100_CR56","year":"2017","issue":null,"author":"ND James","volume":"377","first-page":"338","unstructured":"James, N. D. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N. Engl. J. Med. 377, 338–351 (2017).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1002/jcph.564","key":"1100_CR57","year":"2015","issue":null,"author":"KN Chi","volume":"55","first-page":"1406","unstructured":"Chi, K. N. et al. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. J. Clin. Pharmacol. 55, 1406–1414 (2015).","article-title":null,"journal-title":"J. Clin. Pharmacol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2007.15.9749","key":"1100_CR58","year":"2008","issue":null,"author":"G Attard","volume":"26","first-page":"4563","unstructured":"Attard, G. et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 26, 4563–4571 (2008).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(19)30082-8","key":"1100_CR59","year":"2019","issue":null,"author":"K Fizazi","volume":"20","first-page":"686","unstructured":"Fizazi, K. et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 20, 686–700 (2019).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2025.43.5_suppl.20","key":"1100_CR60","year":"2025","issue":null,"author":"DJ Fisher","volume":"43","first-page":"20","unstructured":"Fisher, D. J. et al. Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD). J. Clin. Oncol. 43, 20–20 (2025).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.20.03488","key":"1100_CR61","year":"2021","issue":null,"author":"KN Chi","volume":"39","first-page":"2294","unstructured":"Chi, K. N. et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J. Clin. Oncol. 39, 2294–2303 (2021).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ejca.2023.113290","key":"1100_CR62","year":"2023","issue":null,"author":"AS Merseburger","volume":"193","first-page":"113290","unstructured":"Merseburger, A. S. et al. Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: a subgroup analysis of the randomised clinical TITAN study. Eur. J. Cancer 193, 113290 (2023).","article-title":null,"journal-title":"Eur. J. Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1530/ETJ-24-0158","key":"1100_CR63","year":"2024","issue":null,"author":"K David","volume":"13","first-page":null,"unstructured":"David, K. et al. Apalutamide-induced severe hypothyroidism: case series and practice recommendations for thyroid management. Eur. Thyroid J. 13, e240158 (2024).","article-title":null,"journal-title":"Eur. Thyroid J.","doi-asserted-by":"publisher"},{"DOI":"10.1210/jendso/bvae105","key":"1100_CR64","year":"2024","issue":null,"author":"C Moffatt","volume":"8","first-page":"bvae105","unstructured":"Moffatt, C. et al. The effect of apalutamide on thyroid function in prostate cancer patients. J. Endocr. Soc. 8, bvae105 (2024).","article-title":null,"journal-title":"J. Endocr. Soc.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(23)00063-3","key":"1100_CR65","year":"2023","issue":null,"author":"CJ Sweeney","volume":"24","first-page":"323","unstructured":"Sweeney, C. J. et al. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 24, 323–334 (2023).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2025.43.16_suppl.5090","key":"1100_CR66","year":"2025","issue":null,"author":"AY Zhang","volume":"43","first-page":"5090","unstructured":"Zhang, A. Y. et al. 8-year outcomes of enzalutamide (ENZA) versus a non-steroidal anti-androgen (NSAA) for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304). J. Clin. Oncol. 43, 5090–5090 (2025).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.21.00941","key":"1100_CR67","year":"2022","issue":null,"author":"MR Stockler","volume":"40","first-page":"837","unstructured":"Stockler, M. R. et al. Health-related quality of life in metastatic, hormone-sensitive prostate cancer: ENZAMET (ANZUP 1304), an international, randomized phase III trial led by ANZUP. J. Clin. Oncol. 40, 837–846 (2022).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1111/bcp.13425","key":"1100_CR68","year":"2018","issue":null,"author":"GE Benoist","volume":"84","first-page":"122","unstructured":"Benoist, G. E. et al. Drug-drug interaction potential in men treated with enzalutamide: Mind the gap. Br. J. Clin. Pharmacol. 84, 122–129 (2018).","article-title":null,"journal-title":"Br. J. Clin. Pharmacol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.19.00799","key":"1100_CR69","year":"2019","issue":null,"author":"AJ Armstrong","volume":"37","first-page":"2974","unstructured":"Armstrong, A. J. et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J. Clin. Oncol. 37, 2974–2986 (2019).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2025.43.16_suppl.5005","key":"1100_CR70","year":"2025","issue":null,"author":"AJ Armstrong","volume":"43","first-page":"5005","unstructured":"Armstrong, A. J. et al. ARCHES: 5-year follow-up overall survival (OS) analysis of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC). J. Clin. Oncol. 43, 5005–5005 (2025).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1007/s13318-019-00577-5","key":"1100_CR71","year":"2019","issue":null,"author":"C Zurth","volume":"44","first-page":"747","unstructured":"Zurth, C. et al. Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur. J. Drug. Metab. Pharmacokinet. 44, 747–759 (2019).","article-title":null,"journal-title":"Eur. J. Drug. Metab. Pharmacokinet.","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamaoncol.2020.7857","key":"1100_CR72","year":"2021","issue":null,"author":"A Ali","volume":"7","first-page":"555","unstructured":"Ali, A. et al. Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 7, 555–563 (2021).","article-title":null,"journal-title":"JAMA Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eururo.2019.02.003","key":"1100_CR73","year":"2019","issue":null,"author":"S Burdett","volume":"76","first-page":"115","unstructured":"Burdett, S. et al. Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: A STOPCAP systematic review and meta-analysis. Eur. Urol. 76, 115–124 (2019).","article-title":null,"journal-title":"Eur. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.euf.2024.06.009","key":"1100_CR74","year":"2025","issue":null,"author":"JE Bibault","volume":"11","first-page":"76","unstructured":"Bibault, J. E., Méjean, A., Hyafil, F., Thibault, C. & Oudard, S. Radiation therapy for locally advanced prostate cancer: how do we treat patients with cN1 disease? Eur. Urol. Focus. 11, 76–78 (2025).","article-title":null,"journal-title":"Eur. Urol. Focus.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(24)01865-8","key":"1100_CR75","year":"2024","issue":null,"author":"A Bossi","volume":"404","first-page":"2065","unstructured":"Bossi, A. et al. Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet 404, 2065–2076 (2024).","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2017.75.4853","key":"1100_CR76","year":"2018","issue":null,"author":"P Ost","volume":"36","first-page":"446","unstructured":"Ost, P. et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J. Clin. Oncol. 36, 446–453 (2018).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamaoncol.2020.0147","key":"1100_CR77","year":"2020","issue":null,"author":"R Phillips","volume":"6","first-page":"650","unstructured":"Phillips, R. et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 6, 650–659 (2020).","article-title":null,"journal-title":"JAMA Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.22.00644","key":"1100_CR78","year":"2022","issue":null,"author":"MP Deek","volume":"40","first-page":"3377","unstructured":"Deek, M. P. et al. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. J. Clin. Oncol. 40, 3377–3382 (2022).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamaoncol.2023.0161","key":"1100_CR79","year":"2023","issue":null,"author":"C Tang","volume":"9","first-page":"825","unstructured":"Tang, C. et al. Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the extend phase 2 randomized clinical trial. JAMA Oncol. 9, 825–834 (2023).","article-title":null,"journal-title":"JAMA Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.euo.2024.03.010","key":"1100_CR80","year":"2024","issue":null,"author":"MP Deek","volume":"7","first-page":"1403","unstructured":"Deek, M. P. et al. Multi-institutional analysis of metastasis-directed therapy with or without androgen deprivation therapy in oligometastatic castration-sensitive prostate cancer. Eur. Urol. Oncol. 7, 1403–1410 (2024).","article-title":null,"journal-title":"Eur. Urol. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.23.00041","key":"1100_CR81","year":"2023","issue":null,"author":"M Hussain","volume":"41","first-page":"3595","unstructured":"Hussain, M. et al. Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial. J. Clin. Oncol. 41, 3595–3607 (2023).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2010.30.7025","key":"1100_CR82","year":"2010","issue":null,"author":"RM Franke","volume":"28","first-page":"4562","unstructured":"Franke, R. M., Carducci, M. A., Rudek, M. A., Baker, S. D. & Sparreboom, A. Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J. Clin. Oncol. 28, 4562–4567 (2010).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eururo.2014.07.020","key":"1100_CR83","year":"2015","issue":null,"author":"G Gandaglia","volume":"68","first-page":"325","unstructured":"Gandaglia, G. et al. Impact of the site of metastases on survival in patients with metastatic prostate cancer. Eur. Urol. 68, 325–334 (2015).","article-title":null,"journal-title":"Eur. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.urolonc.2025.02.007","key":"1100_CR84","year":"2025","issue":null,"author":"F Urabe","volume":"43","first-page":"336.e1","unstructured":"Urabe, F. et al. Locations of metastases in and oncological outcomes of patients with metastatic castration-sensitive prostate cancer: real-world data from a multicenter study. Urol. Oncol. 43, 336.e1–336.e11 (2025).","article-title":null,"journal-title":"Urol. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41391-020-0255-x","key":"1100_CR85","year":"2020","issue":null,"author":"R Iacovelli","volume":"23","first-page":"654","unstructured":"Iacovelli, R. et al. The prognostic value of pain in castration-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 23, 654–660 (2020).","article-title":null,"journal-title":"Prostate Cancer Prostatic Dis.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.euo.2024.04.010","key":"1100_CR86","year":"2025","issue":null,"author":"D Sentana-Lledo","volume":"8","first-page":"29","unstructured":"Sentana-Lledo, D. et al. Patient-reported quality of life and survival outcomes in prostate cancer: analysis of the ECOG-ACRIN E3805 chemohormonal androgen ablation randomized trial (CHAARTED). Eur. Urol. Oncol. 8, 29–37 (2025).","article-title":null,"journal-title":"Eur. Urol. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.clgc.2019.07.009","key":"1100_CR87","year":"2019","issue":null,"author":"K Mori","volume":"17","first-page":"409","unstructured":"Mori, K. et al. Prognostic value of lactate dehydrogenase in metastatic prostate cancer: a systematic review and meta-analysis. Clin. Genitourin. Cancer 17, 409–418 (2019).","article-title":null,"journal-title":"Clin. Genitourin. Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1159/000020289","key":"1100_CR88","year":"2000","issue":null,"author":"A Sella","volume":"38","first-page":"250","unstructured":"Sella, A., Konichezky, M., Flex, D., Sulkes, A. & Baniel, J. Low PSA metastatic androgen- independent prostate cancer. Eur. Urol. 38, 250–254 (2000).","article-title":null,"journal-title":"Eur. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1007/s00432-021-03642-2","key":"1100_CR89","year":"2022","issue":null,"author":"B Lim","volume":"148","first-page":"727","unstructured":"Lim, B. et al. Biopsy-detected Gleason grade 5 tumor is an additional prognostic factor in metastatic hormone-sensitive prostate cancer. J. Cancer Res. Clin. Oncol. 148, 727–734 (2022).","article-title":null,"journal-title":"J. Cancer Res. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eururo.2018.11.045","key":"1100_CR90","year":"2019","issue":null,"author":"AA Hamid","volume":"76","first-page":"89","unstructured":"Hamid, A. A. et al. Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate cancer. Eur. Urol. 76, 89–97 (2019).","article-title":null,"journal-title":"Eur. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41391-021-00430-4","key":"1100_CR91","year":"2022","issue":null,"author":"MG Velez","volume":"25","first-page":"479","unstructured":"Velez, M. G. et al. Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 25, 479–483 (2022).","article-title":null,"journal-title":"Prostate Cancer Prostatic Dis.","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41391-025-00936-1","key":"1100_CR92","year":"2025","issue":null,"author":"G Gebrael","volume":null,"first-page":null,"unstructured":"Gebrael, G. et al. Genomic biomarkers of survival in patients with metastatic hormone-sensitive prostate cancer undergoing intensified androgen deprivation therapy. Prostate Cancer Prostatic Dis. https://doi.org/10.1038/s41391-025-00936-1 (2025).","article-title":null,"journal-title":"Prostate Cancer Prostatic Dis.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eururo.2021.09.030","key":"1100_CR93","year":"2022","issue":null,"author":"RP Graf","volume":"81","first-page":"37","unstructured":"Graf, R. P. et al. Predictive genomic biomarkers of hormonal therapy versus chemotherapy benefit in metastatic castration-resistant prostate cancer. Eur. Urol. 81, 37–47 (2022).","article-title":null,"journal-title":"Eur. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eururo.2024.12.015","key":"1100_CR94","year":"2025","issue":null,"author":"JS de Bono","volume":"87","first-page":"672","unstructured":"de Bono, J. S. et al. Final overall survival and molecular data associated with clinical outcomes in patients receiving ipatasertib and abiraterone in the phase 3 IPATential150 trial. Eur. Urol. 87, 672–682 (2025).","article-title":null,"journal-title":"Eur. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.urolonc.2024.05.010","key":"1100_CR95","year":"2024","issue":null,"author":"S Custodio-Cabello","volume":"42","first-page":"331.e13","unstructured":"Custodio-Cabello, S. et al. Prognostic value of germline mutations in metastatic hormone-sensitive prostate cancer (mHSPC). Urol. Oncol. 42, 331.e13–331.e24 (2024).","article-title":null,"journal-title":"Urol. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamaoncol.2018.5801","key":"1100_CR96","year":"2019","issue":null,"author":"W Abida","volume":"5","first-page":"471","unstructured":"Abida, W. et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol. 5, 471–478 (2019).","article-title":null,"journal-title":"JAMA Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2025.43.16_suppl.TPS5129","key":"1100_CR97","year":"2025","issue":null,"author":"M Ong","volume":"43","first-page":"TPS5129","unstructured":"Ong, M. et al. TRIPLE-SWITCH (SWOG/CCTG-PR26): a randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate cancer (mCSPC) and suboptimal PSA response (NCT06592924). J. Clin. Oncol. 43, TPS5129–TPS5129 (2025).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(24)00440-6","key":"1100_CR98","year":"2024","issue":null,"author":"AA Azad","volume":"25","first-page":"1267","unstructured":"Azad, A. A. et al. Sequential [(177)Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study. Lancet Oncol. 25, 1267–1276 (2024).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.annonc.2025.09.101","key":"1100_CR99","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Tagawa, S. T. et al. LBA6 — Phase III Trial of [177Lu]Lu-PSMA-617 Combined with ADT + ARPI in Patients with PSMA-positive Metastatic Hormone-Sensitive Prostate Cancer (PSMAddition) (ESMO Congress, 2025).","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.1016/j.annonc.2024.08.1739","key":"1100_CR100","year":"2024","issue":null,"author":"M Padden-Modi","volume":"35","first-page":"S999","unstructured":"Padden-Modi, M. et al. 1658TiP The STAMPEDE2 177Lutetium-PSMA-617 (177Lu-PSMA-617) trial: a phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) starting androgen deprivation therapy (ADT). Ann. Oncol. 35, S999–S1000 (2024).","article-title":null,"journal-title":"Ann. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.2217/fon-2023-0526","key":"1100_CR101","year":"2024","issue":null,"author":"N Agarwal","volume":"20","first-page":"493","unstructured":"Agarwal, N. et al. TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer. Future Oncol. 20, 493–505 (2024).","article-title":null,"journal-title":"Future Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2025.43.17_suppl.LBA5006","key":"1100_CR102","year":"2025","issue":null,"author":"G Attard","volume":"43","first-page":"LBA5006","unstructured":"Attard, G. et al. Phase 3 AMPLITUDE trial: niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes. J. Clin. Oncol. 43, LBA5006–LBA5006 (2025).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41591-025-03961-8","key":"1100_CR103","year":"2025","issue":null,"author":"G Attard","volume":null,"first-page":null,"unstructured":"Attard, G. et al. Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial. Nat. Med. https://doi.org/10.1038/s41591-025-03961-8 (2025).","article-title":null,"journal-title":"Nat. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2024.42.16_suppl.TPS5123","key":"1100_CR104","year":"2024","issue":null,"author":"KN Chi","volume":"42","first-page":"TPS5123","unstructured":"Chi, K. N. et al. Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with new hormonal agents in patients with metastatic castration-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01). J. Clin. Oncol. 42, TPS5123–TPS5123 (2024).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.annonc.2024.08.1737","key":"1100_CR105","year":"2024","issue":null,"author":"S Howlett","volume":"35","first-page":"S998","unstructured":"Howlett, S. et al. 1656TiP The STAMPEDE2 niraparib-abiraterone acetate + prednisolone trial: a phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) with a deleterious alteration in a homologous recombination repair (HRR) gene starting androgen deprivation therapy (ADT). Ann. Oncol. 35, S998–S999 (2024).","article-title":null,"journal-title":"Ann. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.annonc.2025.10.004","key":"1100_CR106","year":"2025","issue":null,"author":"K Fizazi","volume":null,"first-page":null,"unstructured":"Fizazi, K. et al. Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study. Ann. Oncol. https://doi.org/10.1016/j.annonc.2025.10.004 (2025).","article-title":null,"journal-title":"Ann. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(21)00580-8","key":"1100_CR107","year":"2021","issue":null,"author":"C Sweeney","volume":"398","first-page":"131","unstructured":"Sweeney, C. et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet 398, 131–142 (2021).","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1212299","key":"1100_CR108","year":"2013","issue":null,"author":"M Hussain","volume":"368","first-page":"1314","unstructured":"Hussain, M. et al. Intermittent versus continuous androgen deprivation in prostate cancer. N. Engl. J. Med. 368, 1314–1325 (2013).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2025.43.5_suppl.268","key":"1100_CR109","year":"2025","issue":null,"author":"A Sokolova","volume":"43","first-page":"268","unstructured":"Sokolova, A. et al. Evaluating survival post-7 mo PSA response, stratified by response, disease extent, and intermittent vs. continuous ADT in mHSPC: The S9346 trial. J. Clin. Oncol. 43, 268–268 (2025).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1093/ageing/afp221","key":"1100_CR110","year":"2010","issue":null,"author":"PN Kannegaard","volume":"39","first-page":"203","unstructured":"Kannegaard, P. N., van der Mark, S., Eiken, P. & Abrahamsen, B. Excess mortality in men compared with women following a hip fracture. national analysis of comedications, comorbidity and survival. Age Ageing 39, 203–209 (2010).","article-title":null,"journal-title":"Age Ageing","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41584-024-01094-9","key":"1100_CR111","year":"2024","issue":null,"author":"NR Fuggle","volume":"20","first-page":"241","unstructured":"Fuggle, N. R. et al. Evidence-based guideline for the management of osteoporosis in men. Nat. Rev. Rheumatol. 20, 241–251 (2024).","article-title":null,"journal-title":"Nat. Rev. Rheumatol.","doi-asserted-by":"publisher"},{"DOI":"10.1007/s11657-018-0510-0","key":"1100_CR112","year":"2018","issue":null,"author":"JA Kanis","volume":"13","first-page":null,"unstructured":"Kanis, J. A., Johansson, H., Harvey, N. C. & McCloskey, E. V. A brief history of FRAX. Arch. Osteoporos. 13, 118 (2018).","article-title":null,"journal-title":"Arch. Osteoporos.","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa0809003","key":"1100_CR113","year":"2009","issue":null,"author":"MR Smith","volume":"361","first-page":"745","unstructured":"Smith, M. R. et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 361, 745–755 (2009).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":"10.1097/JU.0000000000003452","key":"1100_CR114","year":"2023","issue":null,"author":"W Lowrance","volume":"209","first-page":"1082","unstructured":"Lowrance, W. et al. Updates to advanced prostate cancer: AUA/SUO guideline (2023). J. Urol. 209, 1082–1090 (2023).","article-title":null,"journal-title":"J. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2013.51.6500","key":"1100_CR115","year":"2014","issue":null,"author":"MR Smith","volume":"32","first-page":"1143","unstructured":"Smith, M. R. et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J. Clin. Oncol. 32, 1143–1150 (2014).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamanetworkopen.2024.2467","key":"1100_CR116","year":"2024","issue":null,"author":"W Fukuokaya","volume":"7","first-page":null,"unstructured":"Fukuokaya, W. et al. Bone-modifying agents in patients with high-risk metastatic castration-sensitive prostate cancer treated with abiraterone acetate. JAMA Netw. Open. 7, e242467 (2024).","article-title":null,"journal-title":"JAMA Netw. Open.","doi-asserted-by":"publisher"},{"DOI":"10.1161/CIRCULATIONAHA.121.056810","key":"1100_CR117","year":"2021","issue":null,"author":"RD Lopes","volume":"144","first-page":"1295","unstructured":"Lopes, R. D. et al. Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. Circulation 144, 1295–1307 (2021).","article-title":null,"journal-title":"Circulation","doi-asserted-by":"publisher"},{"DOI":"10.1007/s00345-020-03433-3","key":"1100_CR118","year":"2021","issue":null,"author":"P Davey","volume":"39","first-page":"307","unstructured":"Davey, P. & Kirby, M. G. Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice. World J. Urol. 39, 307–315 (2021).","article-title":null,"journal-title":"World J. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2013.49.5523","key":"1100_CR119","year":"2014","issue":null,"author":"JR Gardner","volume":"32","first-page":"335","unstructured":"Gardner, J. R., Livingston, P. M. & Fraser, S. F. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J. Clin. Oncol. 32, 335–346 (2014).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eururo.2014.07.010","key":"1100_CR120","year":"2015","issue":null,"author":"PL Nguyen","volume":"67","first-page":"825","unstructured":"Nguyen, P. L. et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur. Urol. 67, 825–836 (2015).","article-title":null,"journal-title":"Eur. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(09)70338-9","key":"1100_CR121","year":"2010","issue":null,"author":"J Irani","volume":"11","first-page":"147","unstructured":"Irani, J., Salomon, L., Oba, R., Bouchard, P. & Mottet, N. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol. 11, 147–154 (2010).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(23)00085-5","key":"1100_CR122","year":"2023","issue":null,"author":"S Lederman","volume":"401","first-page":"1091","unstructured":"Lederman, S. et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet 401, 1091–1102 (2023).","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMc2412361","key":"1100_CR123","year":"2025","issue":null,"author":"KL Lin","volume":"392","first-page":"202","unstructured":"Lin, K. L., Shekar, S., Crumbaker, M. & Joshua, A. M. Neurokinin-3 receptor antagonism for refractory hot flashes in men. N. Engl. J. Med. 392, 202–203 (2025).","article-title":null,"journal-title":"N. Engl. J. Med.","doi-asserted-by":"publisher"},{"DOI":null,"key":"1100_CR124","year":"2024","issue":null,"author":"D Sentana-Lledo","volume":"23","first-page":null,"unstructured":"Sentana-Lledo, D., Saraf, A. & Morgans, A. K. Symptom burden and survivorship care for patients with prostate cancer on androgen deprivation therapy. J. Natl Compr. Canc. Netw. 23, e247047 (2024).","article-title":null,"journal-title":"J. Natl Compr. Canc. Netw.","doi-asserted-by":null},{"DOI":"10.1038/s41391-023-00785-w","key":"1100_CR125","year":"2024","issue":null,"author":"DE Hinojosa-Gonzalez","volume":"27","first-page":"507","unstructured":"Hinojosa-Gonzalez, D. E. et al. Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 27, 507–519 (2024).","article-title":null,"journal-title":"Prostate Cancer Prostatic Dis.","doi-asserted-by":"publisher"},{"DOI":"10.1002/cncr.31153","key":"1100_CR126","year":"2018","issue":null,"author":"DJ McHugh","volume":"124","first-page":"1326","unstructured":"McHugh, D. J., Root, J. C., Nelson, C. J. & Morris, M. J. Androgen-deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: How much smoke and how much fire? Cancer 124, 1326–1334 (2018).","article-title":null,"journal-title":"Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ejca.2019.04.031","key":"1100_CR127","year":"2019","issue":null,"author":"HJ Boyle","volume":"116","first-page":"116","unstructured":"Boyle, H. J. et al. Updated recommendations of the international society of geriatric oncology on prostate cancer management in older patients. Eur. J. Cancer 116, 116–136 (2019).","article-title":null,"journal-title":"Eur. J. Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41391-022-00541-6","key":"1100_CR128","year":"2023","issue":null,"author":"LG Briggs","volume":"26","first-page":"331","unstructured":"Briggs, L. G. et al. Neurocognitive impairment associated with traditional and novel androgen receptor signaling inhibitors ± androgen deprivation therapy: a pharmacovigilance study. Prostate Cancer Prostatic Dis. 26, 331–337 (2023).","article-title":null,"journal-title":"Prostate Cancer Prostatic Dis.","doi-asserted-by":"publisher"},{"DOI":"10.1210/jcem.87.2.8299","key":"1100_CR129","year":"2002","issue":null,"author":"MR Smith","volume":"87","first-page":"599","unstructured":"Smith, M. R. et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J. Clin. Endocrinol. Metab. 87, 599–603 (2002).","article-title":null,"journal-title":"J. Clin. Endocrinol. Metab.","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamanetworkopen.2024.48707","key":"1100_CR130","year":"2024","issue":null,"author":"N Agarwal","volume":"7","first-page":null,"unstructured":"Agarwal, N. et al. Physician reasons for or against treatment intensification in patients with metastatic prostate cancer. JAMA Netw. Open. 7, e2448707 (2024).","article-title":null,"journal-title":"JAMA Netw. Open.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eururo.2024.09.017","key":"1100_CR131","year":"2025","issue":null,"author":"S Gillessen","volume":"87","first-page":"157","unstructured":"Gillessen, S. et al. Management of patients with advanced prostate cancer. report from the 2024 advanced prostate cancer consensus conference (APCCC). Eur. Urol. 87, 157–216 (2025).","article-title":null,"journal-title":"Eur. Urol.","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.22.00193","key":"1100_CR132","year":"2022","issue":null,"author":"AJ Armstrong","volume":"40","first-page":"1616","unstructured":"Armstrong, A. J. et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J. Clin. Oncol. 40, 1616–1622 (2022).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.euros.2024.06.006","key":"1100_CR133","year":"2024","issue":null,"author":"ME Ahmed","volume":"66","first-page":"38","unstructured":"Ahmed, M. E. et al. Survival patterns based on first-site-specific visceral metastatic prostate cancer: are outcomes of visceral metastases the same? Eur. Urol. Open. Sci. 66, 38–45 (2024).","article-title":null,"journal-title":"Eur. Urol. Open. Sci.","doi-asserted-by":"publisher"},{"DOI":"10.1002/cncr.22971","key":"1100_CR134","year":"2007","issue":null,"author":"PE Spiess","volume":"110","first-page":"1729","unstructured":"Spiess, P. E. et al. Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer 110, 1729–1737 (2007).","article-title":null,"journal-title":"Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamanetworkopen.2024.37871","key":"1100_CR135","year":"2024","issue":null,"author":"A Goldkorn","volume":"7","first-page":null,"unstructured":"Goldkorn, A. et al. Circulating tumor cell count and overall survival in patients with metastatic hormone-sensitive prostate cancer. JAMA Netw. Open. 7, e2437871 (2024).","article-title":null,"journal-title":"JAMA Netw. Open.","doi-asserted-by":"publisher"},{"DOI":"10.1002/pros.24787","key":"1100_CR136","year":"2024","issue":null,"author":"F Matrone","volume":"84","first-page":"1468","unstructured":"Matrone, F. et al. Prognostic value of circulating tumor cells in oligorecurrent hormone-sensitive prostate cancer patients undergoing stereotactic body radiation therapy. Prostate 84, 1468–1478 (2024).","article-title":null,"journal-title":"Prostate","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.clgc.2022.06.016","key":"1100_CR137","year":"2022","issue":null,"author":"AM Lee","volume":"20","first-page":"515","unstructured":"Lee, A. M. et al. The prognostic significance of homologous recombination repair pathway alterations in metastatic hormone sensitive prostate cancer. Clin. Genitourin. Cancer 20, 515–523 (2022).","article-title":null,"journal-title":"Clin. Genitourin. Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.23.02182","key":"1100_CR138","year":"2024","issue":null,"author":"BL Heiss","volume":"42","first-page":"1851","unstructured":"Heiss, B. L. et al. US food and drug administration approval summary: talazoparib in combination with enzalutamide for treatment of patients with homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer. J. Clin. Oncol. 42, 1851–1860 (2024).","article-title":null,"journal-title":"J. Clin. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1158/1078-0432.CCR-20-0168","key":"1100_CR139","year":"2020","issue":null,"author":"KH Stopsack","volume":"26","first-page":"3230","unstructured":"Stopsack, K. H. et al. Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer. Clin. Cancer Res. 26, 3230–3238 (2020).","article-title":null,"journal-title":"Clin. Cancer Res.","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.annonc.2024.08.1677","key":"1100_CR140","year":"2024","issue":null,"author":"E Grist","volume":"35","first-page":"S961","unstructured":"Grist, E. et al. 1596O decipher mRNA score for prediction of survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for advanced prostate cancer (PC): An ancillary study of the STAMPEDE docetaxel trials. Ann. Oncol. 35, S961–S962 (2024).","article-title":null,"journal-title":"Ann. Oncol.","doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(24)00326-7","key":"1100_CR141","year":"2024","issue":null,"author":"MJ Karpinski","volume":"25","first-page":"1188","unstructured":"Karpinski, M. J. et al. Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study. Lancet Oncol. 25, 1188–1201 (2024).","article-title":null,"journal-title":"Lancet Oncol.","doi-asserted-by":"publisher"}],"short-title":[],"update-policy":"https://doi.org/10.1007/springer_crossmark_policy","alternative-id":["1100"],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"original-title":[],"container-title":["Nature Reviews Clinical Oncology"],"reference-count":141,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,11,27]]},"references-count":141,"short-container-title":["Nat Rev Clin Oncol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1038/s41571-025-01100-3","is_oa":false,"title":"Personalized intensification of treatment for hormone-sensitive prostate cancer","updated":"2025-11-28T03:10:16+00:00","published_date":"2025-11-27","best_oa_location":null}},"created_at":"2025-12-08T12:24:58.509Z","updated_at":"2025-12-08T12:24:58.509Z","tags":[{"paper_doi":"10.1038/s41571-025-01100-3","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1038/s41571-025-01100-3","tag_type":"condition","value":"Hormone-Sensitive Prostate Cancer","value_numeric":null},{"paper_doi":"10.1038/s41571-025-01100-3","tag_type":"level_of_evidence","value":"7","value_numeric":null},{"paper_doi":"10.1038/s41571-025-01100-3","tag_type":"modality","value":"AKT Inhibitor","value_numeric":null},{"paper_doi":"10.1038/s41571-025-01100-3","tag_type":"modality","value":"Androgen Receptor Pathway Inhibitor","value_numeric":null},{"paper_doi":"10.1038/s41571-025-01100-3","tag_type":"modality","value":"PARP Inhibitor","value_numeric":null},{"paper_doi":"10.1038/s41571-025-01100-3","tag_type":"modality","value":"Radioligand Therapy","value_numeric":null},{"paper_doi":"10.1038/s41571-025-01100-3","tag_type":"modality","value":"Radiotherapy","value_numeric":null},{"paper_doi":"10.1038/s41571-025-01100-3","tag_type":"modality","value":"Taxane Chemotherapy","value_numeric":null},{"paper_doi":"10.1038/s41571-025-01100-3","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1038/s41571-025-01100-3","tag_type":"warning","value":"Design classification inferred as a narrative review; not specified as systematic.","value_numeric":null},{"paper_doi":"10.1038/s41571-025-01100-3","tag_type":"warning","value":"Narrative review without quantitative outcomes; the abstract provides no effect sizes or event counts.","value_numeric":null},{"paper_doi":"10.1038/s41571-025-01100-3","tag_type":"warning","value":"PSMA PET–defined subgroups are mentioned but not detailed in the abstract.","value_numeric":null}],"summaries":{"what_studied":"Review of how to personalize intensification for hormone‑sensitive prostate cancer, covering selection for ARPIs, docetaxel, and radiotherapy with ADT, the impact of PSMA PET staging, and the status of emerging options (AKT inhibitors, radioligand therapies, PARP inhibitors).","practice_takeaway":"Use disease history and extent on conventional imaging to select patients for ARPIs, docetaxel, and radiotherapy with ADT; consider PSMA PET to refine staging, as it can reveal subgroups where adding docetaxel to ADT plus an ARPI may or may not be appropriate."}},{"doi":"10.1111/1346-8138.17981","pmid":"41041718","title":"Efficacy and Safety of Helical Tomotherapy Combined With Paclitaxel in Cutaneous Angiosarcoma","journal_title":"The Journal of Dermatology","journal_issn":"0385-2407","published_at":"2025-10-03T00:00:00.000Z","url":"https://doi.org/10.1111/1346-8138.17981","source_score":7,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-10-04","doi":"10.1111/1346-8138.17981","days":"14","issn":"0385-2407","rank":"10","field":"Clinical Medicine","score":"7","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1111/1346-8138.17981","title":"Efficacy and Safety of Helical Tomotherapy Combined With Paclitaxel in Cutaneous Angiosarcoma.","journal":"The Journal of dermatology","methods":"","results":"","abstract":"$34","keywords":["chemoradiotherapy","cutaneous angiosarcoma","intensity‐modulated radiation therapy","paclitaxel","prognosis"],"pubmed_id":"41041718","conclusions":"","publication_date":"2025-10-03T00:00:00"},"crossref":{"DOI":"10.1111/1346-8138.17981","URL":"https://doi.org/10.1111/1346-8138.17981","ISSN":["0385-2407","1346-8138"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/1346-8138.17981","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Efficacy and Safety of Helical Tomotherapy Combined With Paclitaxel in Cutaneous Angiosarcoma"],"author":[{"given":"Megumi","family":"Aoki","sequence":"first","affiliation":[{"name":"Department of Dermato‐Oncology NHO Kagoshima Medical Center Kagoshima Japan"}]},{"given":"Kazuyasu","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Dermato‐Oncology NHO Kagoshima Medical Center Kagoshima Japan"},{"name":"Department of Dermatology Kindai University Hospital Osaka Japan"}]},{"given":"Kentaro","family":"Yonekura","sequence":"additional","affiliation":[{"name":"Department of Dermatology Imamura General Hospital Kagoshima Japan"}]},{"given":"Hirotoshi","family":"Nishida","sequence":"additional","affiliation":[{"name":"Department of Radiology Imamura General Hospital Kagoshima Japan"}]},{"given":"Masashi","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Dermato‐Oncology NHO Kagoshima Medical Center Kagoshima Japan"}]},{"given":"Takahisa","family":"Tozawa","sequence":"additional","affiliation":[{"name":"Department of Dermato‐Oncology NHO Kagoshima Medical Center Kagoshima Japan"}]},{"given":"Tokiyoshi","family":"Ikoma","sequence":"additional","affiliation":[{"name":"Department of Dermato‐Oncology NHO Kagoshima Medical Center Kagoshima Japan"}]},{"given":"Shigeto","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Department of Dermato‐Oncology NHO Kagoshima Medical Center Kagoshima Japan"}]}],"issued":{"date-parts":[[2025,10,3]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":null,"archive":["Portico"],"created":{"date-time":"2025-10-03T09:48:56Z","timestamp":1759484936000,"date-parts":[[2025,10,3]]},"indexed":{"date-time":"2025-10-03T10:12:02Z","timestamp":1759486322062,"date-parts":[[2025,10,3]]},"license":[{"URL":"http://onlinelibrary.wiley.com/termsAndConditions#vor","start":{"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000,"date-parts":[[2025,10,3]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":"$35","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.17981"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-08-16"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-09-24"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-10-03"}],"deposited":{"date-time":"2025-10-03T09:48:58Z","timestamp":1759484938000,"date-parts":[[2025,10,3]]},"issn-type":[{"type":"print","value":"0385-2407"},{"type":"electronic","value":"1346-8138"}],"published":{"date-parts":[[2025,10,3]]},"publisher":"Wiley","reference":[{"DOI":"10.3389/fmed.2023.1090168","key":"e_1_2_9_2_1","year":"2023","issue":null,"author":"Guan L.","volume":"10","first-page":null,"unstructured":null,"article-title":"Cutaneous Angiosarcoma: A Review of Current Evidence for Treatment With Checkpoint Inhibitors","journal-title":"Frontiers in Medicine","doi-asserted-by":"crossref"},{"DOI":"10.3389/fonc.2018.00046","key":"e_1_2_9_3_1","year":"2018","issue":null,"author":"Fujisawa Y.","volume":"8","first-page":"46","unstructured":null,"article-title":"Cutaneous Angiosarcoma: The Possibility of New Treatment Options Especially for Patients With Large Primary Tumor","journal-title":"Frontiers in Oncology","doi-asserted-by":"crossref"},{"DOI":"10.3389/fonc.2021.627113","key":"e_1_2_9_4_1","year":"2021","issue":null,"author":"Bi S.","volume":"11","first-page":null,"unstructured":null,"article-title":"The Effectiveness of Different Treatment Modalities of Cutaneous Angiosarcoma: Results From Meta‐Analysis and Observational Data From SEER Database","journal-title":"Frontiers in Oncology","doi-asserted-by":"crossref"},{"DOI":"10.1111/1346-8138.16273","key":"e_1_2_9_5_1","year":"2022","issue":null,"author":"Seo T.","volume":"49","first-page":"383","unstructured":null,"article-title":"Efficacy of a Combination of Paclitaxel and Radiation Therapy Against Cutaneous Angiosarcoma: A Single‐Institution Retrospective Study of 21 Cases","journal-title":"Journal of Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00066-023-02093-7","key":"e_1_2_9_6_1","year":"2024","issue":null,"author":"Hama Y.","volume":"200","first-page":"123","unstructured":null,"article-title":"High‐Dose Planned Adaptive Helical Tomotherapy for Cutaneous Angiosarcoma of the Scalp","journal-title":"Strahlentherapie und Onkologie","doi-asserted-by":"crossref"},{"DOI":"10.1097/MD.0000000000028210","key":"e_1_2_9_7_1","year":"2021","issue":null,"author":"Suzuki G.","volume":"100","first-page":null,"unstructured":null,"article-title":"A Successful Approach for Angiosarcoma of the Scalp Using Helical Tomotherapy and Customized Surface Mold Brachytherapy: A Case Report","journal-title":"Medicine (Baltimore)","doi-asserted-by":"crossref"},{"DOI":"10.21873/anticanres.16110","key":"e_1_2_9_8_1","year":"2022","issue":null,"author":"Okano N.","volume":"42","first-page":"5991","unstructured":null,"article-title":"Definitive Radiotherapy Using Electron Beam and Intensity‐Modulated Radiotherapy for Unresectable Angiosarcoma of the Scalp","journal-title":"Anticancer Research","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjd.13110","key":"e_1_2_9_9_1","year":"2014","issue":null,"author":"Fujisawa Y.","volume":"171","first-page":"1493","unstructured":null,"article-title":"Chemoradiotherapy With Taxane Is Superior to Conventional Surgery and Radiotherapy in the Management of Cutaneous Angiosarcoma: A Multicentre, Retrospective Study","journal-title":"British Journal of Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1093/jrr/rrad089","key":"e_1_2_9_10_1","year":"2024","issue":null,"author":"Iwai T.","volume":"65","first-page":"78","unstructured":null,"article-title":"Clinical Outcomes of Scalp or Face Angiosarcoma Treatment With Intensity‐Modulated Radiotherapy: A Multicenter Study","journal-title":"Journal of Radiation Research","doi-asserted-by":"crossref"}],"short-title":[],"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/1346-8138.17981"],"article-number":"1346-8138.17981","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["The Journal of Dermatology"],"reference-count":9,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,10,3]]},"references-count":9,"short-container-title":["The Journal of Dermatology"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1111/1346-8138.17981","is_oa":false,"title":"Efficacy and Safety of Helical Tomotherapy Combined With Paclitaxel in Cutaneous Angiosarcoma","updated":"2025-10-04T00:06:06+00:00","published_date":"2025-10-03","best_oa_location":null}},"created_at":"2025-10-06T07:08:34.463Z","updated_at":"2025-10-16T07:50:39.785Z","tags":[{"paper_doi":"10.1111/1346-8138.17981","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17981","tag_type":"condition","value":"Cutaneous Angiosarcoma","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17981","tag_type":"generic","value":"paclitaxel","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17981","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17981","tag_type":"level_of_evidence","value":"6","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17981","tag_type":"modality","value":"Radiation Therapy","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17981","tag_type":"modality","value":"Taxane Chemotherapy","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17981","tag_type":"sample_size","value":"n=12","value_numeric":12},{"paper_doi":"10.1111/1346-8138.17981","tag_type":"study_design","value":"Case Series","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17981","tag_type":"warning","value":"Comparative statements rely on historical controls; no concurrent control arm is described.","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17981","tag_type":"warning","value":"Design appears to be a single-arm retrospective series; classification between case series and retrospective cohort may be ambiguous.","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17981","tag_type":"warning","value":"Details on radiation dose, fields, and paclitaxel schedule are not provided in the abstract.","value_numeric":null}],"summaries":{"what_studied":"Retrospective review of 12 patients with cutaneous angiosarcoma treated with helical tomotherapy plus paclitaxel between January 2017 and April 2024, assessing progression-free survival, overall survival, and adverse events, with comparison to historical controls.","key_result":"Median progression-free survival was 10.5 months (95% CI, 7.7–not reached). Two-year overall survival and progression-free survival rates were 70.0% and 41.7%, respectively; grade ≥3 adverse events included radiation dermatitis (n=1), neutropenia (n=2), peripheral neuropathy (n=1), and corneal toxicity (n=1).","limitations":"Very small sample size (n=12) and retrospective design; outcomes were compared only with historical controls without a concurrent comparator.","practice_takeaway":"When using tomotherapy with paclitaxel for cutaneous angiosarcoma, clinicians can counsel that this series observed a 2-year overall survival of 70% and limited grade ≥3 toxicities, while emphasizing the evidence is from a small retrospective cohort."}},{"doi":"10.1111/1346-8138.17960","pmid":"40958441","title":"A Case of Taxane‐Induced Scleroderma Presenting in a Unilateral Upper Limb and a Literature Review","journal_title":"The Journal of Dermatology","journal_issn":"0385-2407","published_at":"2025-09-17T00:00:00.000Z","url":"https://doi.org/10.1111/1346-8138.17960","source_score":2,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-09-23","doi":"10.1111/1346-8138.17960","days":"7","issn":"0385-2407","rank":"10","field":"Clinical Medicine","score":"2","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1111/1346-8138.17960","title":"A Case of Taxane-Induced Scleroderma Presenting in a Unilateral Upper Limb and a Literature Review.","journal":"The Journal of dermatology","methods":"","results":"","abstract":"A 64-year-old woman with progressive thickening of the skin on her left upper limb was referred to our clinic. She had previously undergone partial mastectomy and axillary lymph node dissection for left-sided breast cancer, followed by postoperative radiation therapy and chemotherapy with docetaxel. She exhibited edema and sclerosis of the left arm and contracture limited to the fingers of the left hand, while her right arm and lower extremities remained unaffected. There were no signs of Raynaud's phenomenon or periungual capillary abnormalities suggestive of systemic sclerosis. Skin biopsy from the left forearm showed dermal thickening with swollen collagen fibers throughout the dermis. A diagnosis of unilateral docetaxel-induced scleroderma was established. Taxane-induced scleroderma typically manifests symmetrically in the lower limbs with prominent edema. This report describes a rare case of unilateral upper limb involvement and discusses its characteristics with a review of previously reported cases.","keywords":[],"pubmed_id":"40958441","conclusions":"","publication_date":"2025-09-17T00:00:00"},"crossref":{"DOI":"10.1111/1346-8138.17960","URL":"https://doi.org/10.1111/1346-8138.17960","ISSN":["0385-2407","1346-8138"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/1346-8138.17960","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["A Case of Taxane‐Induced Scleroderma Presenting in a Unilateral Upper Limb and a Literature Review"],"author":[{"given":"Mana","family":"Sekine","sequence":"first","affiliation":[{"name":"Department of Dermatology Tohoku University Graduate School of Medicine Sendai Miyagi Japan"}]},{"given":"Takehiro","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Dermatology Tohoku University Graduate School of Medicine Sendai Miyagi Japan"}]},{"given":"Saki","family":"Okuda","sequence":"additional","affiliation":[{"name":"Department of Dermatology Osaki Citizen Hospital Osaki Miyagi Japan"}]},{"given":"Naokazu","family":"Hatchome","sequence":"additional","affiliation":[{"name":"Department of Dermatology Tohoku University Graduate School of Medicine Sendai Miyagi Japan"}]},{"given":"Hidetoshi","family":"Mitsui","sequence":"additional","affiliation":[{"name":"Department of Dermatology Osaki Citizen Hospital Osaki Miyagi Japan"}]},{"given":"Taku","family":"Fujimura","sequence":"additional","affiliation":[{"name":"Department of Dermatology Tohoku University Graduate School of Medicine Sendai Miyagi Japan"}]},{"given":"Setsuya","family":"Aiba","sequence":"additional","affiliation":[{"name":"Department of Dermatology Tohoku University Graduate School of Medicine Sendai Miyagi Japan"}]},{"given":"Yoshihide","family":"Asano","sequence":"additional","affiliation":[{"name":"Department of Dermatology Tohoku University Graduate School of Medicine Sendai Miyagi Japan"}]}],"issued":{"date-parts":[[2025,9,16]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":null,"archive":["Portico"],"created":{"date-time":"2025-09-17T05:43:00Z","timestamp":1758087780000,"date-parts":[[2025,9,17]]},"indexed":{"date-time":"2025-09-18T10:26:05Z","timestamp":1758191165248,"date-parts":[[2025,9,18]]},"license":[{"URL":"http://onlinelibrary.wiley.com/termsAndConditions#vor","start":{"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000,"date-parts":[[2025,9,16]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":"$36","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.17960"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-06-30"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-09-11"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-09-16"}],"deposited":{"date-time":"2025-09-17T05:43:03Z","timestamp":1758087783000,"date-parts":[[2025,9,17]]},"issn-type":[{"type":"print","value":"0385-2407"},{"type":"electronic","value":"1346-8138"}],"published":{"date-parts":[[2025,9,16]]},"publisher":"Wiley","reference":[{"DOI":"10.1016/j.alit.2021.08.005","key":"e_1_2_6_2_1","year":"2022","issue":"2","author":"Hamaguchi Y.","volume":"71","first-page":"163","unstructured":null,"article-title":"Drug‐Induced Scleroderma‐Like Lesion","journal-title":"Allergology International","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-2230.2004.01519.x","key":"e_1_2_6_3_1","year":"2004","issue":"4","author":"Farrant P. B. J.","volume":"29","first-page":"360","unstructured":null,"article-title":"Scleroderma and the Taxanes. Is There Really a Link?","journal-title":"Clinical and Experimental Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-2230.2004.01668.x","key":"e_1_2_6_4_1","year":"2005","issue":"2","author":"Alexandrescu D. T.","volume":"30","first-page":"141","unstructured":null,"article-title":"Chemotherapy‐Induced Scleroderma: A Pleiomorphic Syndrome","journal-title":"Clinical and Experimental Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-2133.2006.07597.x","key":"e_1_2_6_5_1","year":"2007","issue":"2","author":"Itoh M.","volume":"156","first-page":"363","unstructured":null,"article-title":"Taxane‐Induced Scleroderma","journal-title":"British Journal of Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1007/s10067-022-06364-z","key":"e_1_2_6_6_1","year":"2022","issue":"12","author":"Ketpueak T.","volume":"41","first-page":"3887","unstructured":null,"article-title":"Paclitaxel‐Induced Diffuse Scleroderma With Possible Scleroderma‐Renal Crisis: A Case Report and Literature Review of Taxanes‐Induced Scleroderma","journal-title":"Clinical Rheumatology","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-2133.2011.10243.x","key":"e_1_2_6_7_1","year":"2011","issue":"6","author":"Takahashi T.","volume":"164","first-page":"1393","unstructured":null,"article-title":"A Case of Taxane‐Induced Scleroderma: A Different Expression Profile of Fli1 Proteins in Dermal Fibroblasts and Microvascular Endothelial Cells Compared With Systemic Sclerosis","journal-title":"British Journal of Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.kint.2016.11.029","key":"e_1_2_6_8_1","year":"2017","issue":"1","author":"Siddall E.","volume":"92","first-page":"37","unstructured":null,"article-title":"Capillary Leak Syndrome: Etiologies, Pathophysiology, and Management","journal-title":"Kidney International","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjd.13899","key":"e_1_2_6_9_1","year":"2015","issue":"4","author":"Okada K.","volume":"173","first-page":"1054","unstructured":null,"article-title":"Glycosaminoglycan and Versican Deposits in Taxane‐Induced Sclerosis","journal-title":"British Journal of Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1111/1756-185X.12697","key":"e_1_2_6_10_1","year":"2017","issue":"11","author":"Yang J. Q.","volume":"20","first-page":"1835","unstructured":null,"article-title":"Docetaxel‐Induced Scleroderma: A Case Report and Its Role in the Production of Extracellular Matrix","journal-title":"International Journal of Rheumatic Diseases","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.yexcr.2017.12.018","key":"e_1_2_6_11_1","year":"2018","issue":"2","author":"Millrud C. R.","volume":"362","first-page":"525","unstructured":null,"article-title":"Docetaxel Promotes the Generation of Anti‐Tumorigenic Human Macrophages","journal-title":"Experimental Cell Research","doi-asserted-by":"crossref"},{"DOI":"10.3390/medicina60071092","key":"e_1_2_6_12_1","year":"2024","issue":"7","author":"Pai H. L.","volume":"60","first-page":null,"unstructured":null,"article-title":"Scleroderma‐Like Lesions in a Patient Undergoing Combined Pembrolizumab and Routine Chemotherapy: A Case Report and Literature Review","journal-title":"Medicina (Kaunas, Lithuania)","doi-asserted-by":"crossref"},{"DOI":"10.1001/archdermatol.2008.532","key":"e_1_2_6_13_1","year":"2009","issue":"1","author":"Kawakami T.","volume":"145","first-page":"97","unstructured":null,"article-title":"Limited Cutaneous Systemic Sclerosis Induced by Paclitaxel in a Patient With Breast Cancer","journal-title":"Archives of Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.5152/tjbh.2015.1879","key":"e_1_2_6_14_1","year":"2015","issue":"2","author":"Kılıç M.","volume":"11","first-page":"95","unstructured":null,"article-title":"Docetaxel‐Induced Scleroderma in A Breast Cancer Patient: A Case Report","journal-title":"Journal of Breast Health","doi-asserted-by":"crossref"}],"short-title":[],"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/1346-8138.17960"],"article-number":"1346-8138.17960","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["The Journal of Dermatology"],"reference-count":13,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,9,16]]},"references-count":13,"short-container-title":["The Journal of Dermatology"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1111/1346-8138.17960","is_oa":false,"title":"A Case of Taxane‐Induced Scleroderma Presenting in a Unilateral Upper Limb and a Literature Review","updated":"2025-09-18T09:59:37+00:00","published_date":"2025-09-16","best_oa_location":null}},"created_at":"2025-09-30T13:03:24.817Z","updated_at":"2025-09-30T13:03:24.817Z","tags":[{"paper_doi":"10.1111/1346-8138.17960","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17960","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17960","tag_type":"condition","value":"Drug-Induced Scleroderma","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17960","tag_type":"generic","value":"docetaxel","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17960","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17960","tag_type":"level_of_evidence","value":"6","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17960","tag_type":"modality","value":"Taxane Chemotherapy","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17960","tag_type":"sample_size","value":"n=1","value_numeric":1},{"paper_doi":"10.1111/1346-8138.17960","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17960","tag_type":"study_design","value":"Case Report","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17960","tag_type":"warning","value":"Causality with docetaxel is inferred from one case and is not proven.","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17960","tag_type":"warning","value":"Design classification is approximate; the article includes a literature review in addition to a single case.","value_numeric":null},{"paper_doi":"10.1111/1346-8138.17960","tag_type":"warning","value":"Only the abstract was available; management and outcomes were not reported.","value_numeric":null}],"summaries":{"what_studied":"A case report of unilateral upper-limb scleroderma after docetaxel for breast cancer, with a brief literature review.","key_result":"One 64-year-old woman developed edema, sclerosis, and finger contractures limited to the left arm after docetaxel; the right limbs were unaffected, Raynaud’s and periungual capillary changes were absent, and skin biopsy showed dermal thickening with swollen collagen fibers.","limitations":"Single-patient report with no comparator or outcome data; details of the literature review are not provided in the abstract.","practice_takeaway":"Docetaxel can trigger localized, unilateral scleroderma without Raynaud’s or nailfold changes; consider biopsy to confirm when new, limb-limited sclerosis appears after taxane therapy."}}],"initialOffset":6,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"Taxane Chemotherapy"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"Taxane Chemotherapy"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"Taxane Chemotherapy"}}}]]

Papers